yapfuiping personal page - To The Moon

yapfuiping

yapfuiping

No personal profile

451Follow

19Followers

0Topic

0Badge

2023-12-11

Good job and do it better

2022-10-28

Good

2022-10-28

Good

Sorry, the original content has been removed

2022-09-16

Good

Tightening expectations are up again! U.S. mortgage interest rates break through the 6% mark for the first time since 2008

2022-09-16

Good

Sorry, the original content has been removed

2022-06-08

Good

Sorry, the original content has been removed

2022-06-08

Good

Investors Don't Think U.S. Recession Is Coming: BofA Strategist

2022-05-25

Good

Sorry, the original content has been removed

2022-05-25

Good

Has U.S. debt passed its lowest point? Wall Street veterans decided to take a gamble

2022-05-25

Good

Sorry, the original content has been removed

2022-05-09

Good

Sorry, the original content has been removed

2022-04-19

good

@投资界:精“材”路演上线！「创投W+」新材料专场路演顺利举行

2022-04-12

Good

Sorry, the original content has been removed

2022-02-10

Good

Lepu Biotech starts its IPO today, with an admission fee of HK$7454.38

2022-02-08

Good

Sorry, the original content has been removed

2022-02-07

Good

Sorry, the original content has been removed

2022-01-13

Good

Sorry, the original content has been removed

2022-01-13

Good

Sorry, the original content has been removed

2022-01-13

Good

Sorry, the original content has been removed

2022-01-11

Good

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4089010487435940","uuid":"4089010487435940","gmtCreate":1625907452109,"gmtModify":1706620741444,"name":"yapfuiping","pinyin":"yapfuiping","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","hatId":"shopping-5c7909103804749e0b21df6dfddc9bae","hatName":"2024 New Year frame","vip":1,"status":2,"fanSize":19,"headSize":451,"tweetSize":44,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":250806779003056,"gmtCreate":1702251264994,"gmtModify":1702251269072,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good job and do it better&nbsp;","listText":"Good job and do it better&nbsp;","text":"Good job and do it better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/250806779003056","isVote":1,"tweetType":1,"viewCount":4386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9986277997,"gmtCreate":1666971145119,"gmtModify":1676537842854,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986277997","isVote":1,"tweetType":1,"viewCount":3496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9986274431,"gmtCreate":1666971111523,"gmtModify":1676537842846,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986274431","repostId":"1185917497","repostType":4,"isVote":1,"tweetType":1,"viewCount":3265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934222382,"gmtCreate":1663260443546,"gmtModify":1676537239038,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934222382","repostId":"2267068823","repostType":4,"repost":{"id":"2267068823","kind":"news","pubTimestamp":1663254748,"share":"https://ttm.financial/m/news/2267068823?lang=en_US&edition=fundamental","pubTime":"2022-09-15 23:12","market":"us","language":"zh","title":"Tightening expectations are up again! U.S. mortgage interest rates break through the 6% mark for the first time since 2008","url":"https://stock-news.laohu8.com/highlight/detail?id=2267068823","media":"华尔街见闻","summary":"高涨的房贷利率严重挤压房地产贷款需求，更多的购房者开始持币观望。伴随着美联储政策持续收紧，美国最受欢迎的住房贷款平均利率自2008年以来首次升至6%以上。抵押贷款银行家协会（MBA）数据显示，截至9月","content":"<p><html><head></head><body>The high mortgage interest rate has seriously squeezed the demand for real estate loans, and more buyers have begun to wait and see. The average interest rate on the nation's most popular home loan has risen above 6% for the first time since 2008 as the Federal Reserve continues to tighten policy.</p><p>The U.S. 30-year fixed mortgage rate rose to 6.01% in the week ending Sept. 9, crossing the 6% mark for the first time since 2008 and twice as much as a year earlier, according to Mortgage Bankers Association (MBA) data.</p><p><img src=\"https://static.tigerbbs.com/1d221eff5a83aecbb6996b21f7f45d5a\" tg-width=\"550\" tg-height=\"344\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>High mortgage interest rates are severely squeezing real estate loan demand.</b>Applications for mortgage purchases were down 29% in the week ending Sept. 9 compared to the same period in 2021. The market composite index, which measures mortgage applications, fell 1.2% from the previous week. The MBA Refinance Index fell 4% from the previous week and 83% from the same period last year. Joel Kan, MBA's vice president of economic and industry forecasting, said,<b>Rising mortgage rates are causing more homebuyers to hold their currency.</b></p><p>As the Federal Reserve continues to raise interest rates, the entire U.S. real estate industry is affected by higher interest rates. Previous data showed that new home sales in the United States in July were 12.6% larger than the previous month, which was significantly less than the expected drop of 2.5%. New home sales fell month-on-month in six of the past seven months. Sales shrank to the lowest level in six and a half years.</p><p><img src=\"https://static.tigerbbs.com/6f3a07a596f24e18a871d1e6cc1b627a\" tg-width=\"550\" tg-height=\"290\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>The sluggish sales coincided with high inventories of new homes in the United States. At the end of July, there were 464,000 new homes for sale, the most since 2008. At the current rate of sales, it will take 10.9 months to empty the supply of new homes, the highest inventory-to-sales ratio since March 2009 and nearly double the rate at the start of the year.</p><p><img src=\"https://static.tigerbbs.com/5da9e4aaf175e9be328df0ab07033077\" tg-width=\"550\" tg-height=\"301\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Although the new home market only accounts for 10% of the U.S. property market, the new home sales are calculated according to the data at the time of signing the home purchase contract, which is different from the existing home sales that are included in the statistics after signing the contract, so it is regarded as the leading indicator of the U.S. property market.<b>Some market analysts believe that in view of the plunge in mortgage loan applications, new home sales are expected to decline further in the future.</b></p><p></body></html></p>","source":"wallstreetcn_api","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tightening expectations are up again! U.S. mortgage interest rates break through the 6% mark for the first time since 2008</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTightening expectations are up again! U.S. mortgage interest rates break through the 6% mark for the first time since 2008\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">华尔街见闻</strong><span class=\"h-time small\">2022-09-15 23:12</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>The high mortgage interest rate has seriously squeezed the demand for real estate loans, and more buyers have begun to wait and see. The average interest rate on the nation's most popular home loan has risen above 6% for the first time since 2008 as the Federal Reserve continues to tighten policy.</p><p>The U.S. 30-year fixed mortgage rate rose to 6.01% in the week ending Sept. 9, crossing the 6% mark for the first time since 2008 and twice as much as a year earlier, according to Mortgage Bankers Association (MBA) data.</p><p><img src=\"https://static.tigerbbs.com/1d221eff5a83aecbb6996b21f7f45d5a\" tg-width=\"550\" tg-height=\"344\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>High mortgage interest rates are severely squeezing real estate loan demand.</b>Applications for mortgage purchases were down 29% in the week ending Sept. 9 compared to the same period in 2021. The market composite index, which measures mortgage applications, fell 1.2% from the previous week. The MBA Refinance Index fell 4% from the previous week and 83% from the same period last year. Joel Kan, MBA's vice president of economic and industry forecasting, said,<b>Rising mortgage rates are causing more homebuyers to hold their currency.</b></p><p>As the Federal Reserve continues to raise interest rates, the entire U.S. real estate industry is affected by higher interest rates. Previous data showed that new home sales in the United States in July were 12.6% larger than the previous month, which was significantly less than the expected drop of 2.5%. New home sales fell month-on-month in six of the past seven months. Sales shrank to the lowest level in six and a half years.</p><p><img src=\"https://static.tigerbbs.com/6f3a07a596f24e18a871d1e6cc1b627a\" tg-width=\"550\" tg-height=\"290\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>The sluggish sales coincided with high inventories of new homes in the United States. At the end of July, there were 464,000 new homes for sale, the most since 2008. At the current rate of sales, it will take 10.9 months to empty the supply of new homes, the highest inventory-to-sales ratio since March 2009 and nearly double the rate at the start of the year.</p><p><img src=\"https://static.tigerbbs.com/5da9e4aaf175e9be328df0ab07033077\" tg-width=\"550\" tg-height=\"301\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Although the new home market only accounts for 10% of the U.S. property market, the new home sales are calculated according to the data at the time of signing the home purchase contract, which is different from the existing home sales that are included in the statistics after signing the contract, so it is regarded as the leading indicator of the U.S. property market.<b>Some market analysts believe that in view of the plunge in mortgage loan applications, new home sales are expected to decline further in the future.</b></p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://wallstreetcn.com/articles/3670388\">华尔街见闻</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c3c5822c22b6cfd1d0ae2625b7bc085e","relate_stocks":{},"source_url":"https://wallstreetcn.com/articles/3670388","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2267068823","content_text":"高涨的房贷利率严重挤压房地产贷款需求，更多的购房者开始持币观望。伴随着美联储政策持续收紧，美国最受欢迎的住房贷款平均利率自2008年以来首次升至6%以上。抵押贷款银行家协会（MBA）数据显示，截至9月9日当周，美国30年期固定抵押贷款利率升至6.01%，为2008年以来首次突破6%关口，是去年同期的两倍。高涨的房贷利率严重挤压房地产贷款需求。截至9月9日当周，抵押贷款购房申请比2021年同期下降了29%。衡量抵押贷款申请量的市场综合指数较前一周下降了1.2%。MBA再融资指数较前一周下降了4%，较去年同期下降了83%。MBA负责经济和行业预测的副总裁Joel Kan表示，抵押贷款利率上升导致更多购房者持币观望。伴随着美联储持续升息，整个美国房地产行业都受到更高利率的影响。此前数据显示，美国7月新屋销售环比大12.6%，大幅不及预期的下跌2.5%，新屋销售在过去七个月中，有六个月环比下跌。销售量萎缩至六年半以来的最低水平。销售萎靡的同时，美国新屋库存高企。截至7月末，有46.4万套新房待售，为2008年以来最多。按照目前的销售速度计算，将需要10.9个月才能清空新房供应，这是自2009年3月以来的最高库销比，几乎是今年年初的两倍。新屋市场虽仅占美国楼市的一成，但新屋销售按照签订购房合同之时的数据计算，与签约完成再纳入统计的成屋销售有所区别，因此被视为美国楼市的领先指标。有市场分析认为，鉴于房屋按揭贷款申请的暴跌，新屋销售未来预计仍将进一步下跌。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2848,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934222915,"gmtCreate":1663260376337,"gmtModify":1676537239022,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9934222915","repostId":"2267687636","repostType":4,"isVote":1,"tweetType":1,"viewCount":4178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9051335618,"gmtCreate":1654644895034,"gmtModify":1676535482645,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9051335618","repostId":"2241270077","repostType":4,"isVote":1,"tweetType":1,"viewCount":2564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9051335184,"gmtCreate":1654644877348,"gmtModify":1676535482645,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9051335184","repostId":"2241907023","repostType":4,"repost":{"id":"2241907023","kind":"news","pubTimestamp":1654643193,"share":"https://ttm.financial/m/news/2241907023?lang=en_US&edition=fundamental","pubTime":"2022-06-08 07:06","market":"hk","language":"zh","title":"Investors Don't Think U.S. Recession Is Coming: BofA Strategist","url":"https://stock-news.laohu8.com/highlight/detail?id=2241907023","media":"环球市场播报","summary":"策略师们表示， 美国银行客户并不认为经济衰退即将来临，自2021年7月以来，流入美国周期性股票的资金继续超过流入防御性股票的资金。Jill Carey Hall等策略师在报告中写道，美银客户上周成为美国股票的净买家，散户客户居首。客户买入单一股票，ETF则出现1月以来最大资金流出；中型股被买入，大盘股和小盘股遭抛售。需要注意到的是，随着财报季结束，股票回购速度较前一周有所放缓。策略师表示，标普500指数11个行业板块中8个走高，科技和非必需消费品股领涨。股民福利来了！十大金股送给你，带你掘金“黄金坑”！点击查看>>","content":"<p><html><head></head><body>Strategists say,<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>Clients don't see a recession coming, and since July 2021, money has continued to flow into U.S. cyclical stocks more than into defensive stocks.</p><p>Bank of America clients became net buyers of U.S. stocks last week, with retail clients leading the way, strategists such as Jill Carey Hall wrote in the report.</p><p>Customers buy a single stock,<a href=\"https://laohu8.com/S/PSFF\">Pacer Swan SOS Fund of Funds ETF | ETF</a>The largest capital outflow since January; Mid-cap stocks were bought and large-cap and small-cap stocks sold off.</p><p>It is important to note that the pace of share buybacks has slowed from the previous week as earnings season ends.</p><p>Eight of the 11 sector sectors in the S&P 500 were higher, with technology and consumer discretionary stocks leading gains, strategists said.</p><p></body></html></p>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors Don't Think U.S. Recession Is Coming: BofA Strategist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors Don't Think U.S. Recession Is Coming: BofA Strategist\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">环球市场播报</strong><span class=\"h-time small\">2022-06-08 07:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Strategists say,<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>Clients don't see a recession coming, and since July 2021, money has continued to flow into U.S. cyclical stocks more than into defensive stocks.</p><p>Bank of America clients became net buyers of U.S. stocks last week, with retail clients leading the way, strategists such as Jill Carey Hall wrote in the report.</p><p>Customers buy a single stock,<a href=\"https://laohu8.com/S/PSFF\">Pacer Swan SOS Fund of Funds ETF | ETF</a>The largest capital outflow since January; Mid-cap stocks were bought and large-cap and small-cap stocks sold off.</p><p>It is important to note that the pace of share buybacks has slowed from the previous week as earnings season ends.</p><p>Eight of the 11 sector sectors in the S&P 500 were higher, with technology and consumer discretionary stocks leading gains, strategists said.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/usstock/c/2022-06-07/doc-imizmscu5622440.shtml\">环球市场播报</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/5e9ba109e7f6844f2904f6647779f151","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","UPRO":"三倍做多标普500ETF-ProShares","BK4504":"桥水持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","IVV":"标普500ETF-iShares",".SPX":"S&P 500 Index","BK4207":"综合性银行","SPXU":"三倍做空标普500ETF-ProShares","BK4581":"高盛持仓","SH":"做空标普500-Proshares","BK4553":"喜马拉雅资本持仓","SPY":"标普500ETF","BAC":"美国银行","OEF":"标普100指数ETF-iShares","BK4534":"瑞士信贷持仓","SSO":"2倍做多标普500ETF-ProShares","OEX":"标普100","SDS":"两倍做空标普500 ETF-ProShares"},"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/usstock/c/2022-06-07/doc-imizmscu5622440.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2241907023","content_text":"策略师们表示， 美国银行客户并不认为经济衰退即将来临，自2021年7月以来，流入美国周期性股票的资金继续超过流入防御性股票的资金。Jill Carey Hall等策略师在报告中写道，美银客户上周成为美国股票的净买家，散户客户居首。客户买入单一股票，Pacer Swan SOS Fund of Funds ETF|ETF则出现1月以来最大资金流出；中型股被买入，大盘股和小盘股遭抛售。需要注意到的是，随着财报季结束，股票回购速度较前一周有所放缓。策略师表示，标普500指数11个行业板块中8个走高，科技和非必需消费品股领涨。","news_type":1,"symbols_score_info":{"161125":0.6,"513500":0.6,"SSO":0.6,"OEF":0.6,"SPY":0.9,"OEX":0.6,"UPRO":0.6,"ESmain":0.6,".SPX":0.6,"BAC":0.9,"SH":0.6,"SDS":0.6,"IVV":0.6,"SPXU":0.6}},"isVote":1,"tweetType":1,"viewCount":2986,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9026712553,"gmtCreate":1653435450372,"gmtModify":1676535280170,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026712553","repostId":"2238304789","repostType":4,"isVote":1,"tweetType":1,"viewCount":4030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9026716559,"gmtCreate":1653435408272,"gmtModify":1676535280154,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026716559","repostId":"2238371098","repostType":4,"repost":{"id":"2238371098","kind":"news","pubTimestamp":1653433904,"share":"https://ttm.financial/m/news/2238371098?lang=en_US&edition=fundamental","pubTime":"2022-05-25 07:11","market":"sh","language":"zh","title":"Has U.S. debt passed its lowest point? Wall Street veterans decided to take a gamble","url":"https://stock-news.laohu8.com/highlight/detail?id=2238371098","media":"环球市场播报","summary":"从贝莱德到T． Rowe Price Group Inc．，华尔街一些对判断债市荣枯颇有经验的市场老手看到了预示可重新买入的迹象。　　但没有人急着下市场见底的判断，因为美国通胀率仍处于四十年高点，而且美联储刚开始收紧货币政策。　　但是，今年以来美国国债收益率已经飙升了许多，其中10年期国债收益率上涨近一倍，令人回想起上一次退潮时被证明时机不错的买入窗口。10年期国债收益率周二盘中一度下挫13基点至2.72%，创4月27日以来最低水平。","content":"<p><html><head></head><body>From<a href=\"https://laohu8.com/S/BLK\">BlackRock</a>By T. Rowe Price Group Inc., some Wall Street veterans experienced in judging bond markets saw signs of re-buying.</p><p>But no one is rushing to judge that the market is bottoming out, because U.S. inflation is still at a four-decade high and the Federal Reserve is just beginning to tighten monetary policy.</p><p>However, U.S. Treasury Bond yields have soared a lot this year, with the 10-year Treasury Bond yield nearly doubling, recalling the proven well-timed buying window at the last ebb. On top of that, there are signs that the economy is cooling, with large retailers reporting changes in consumer spending and declining residential sales. The fall in risky assets such as growth stocks and cryptocurrencies has made the U.S. Treasury Bond a safe haven again, with investors who entered the market to buy when yields peaked earlier this month getting good returns.</p><p>All of this gives long-term fund managers a reason to cautiously increase their exposure, with some prepared to pick up their buying pace when yields exceed what they see as reasonable.<a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Asset Management's global interest rate chief said that the most violent phase of the U.S. debt decline was over, as the prospect of a rate hike by the Federal Reserve was largely absorbed by the market.</p><p>David Giroux, head of Investment strategy at T. Rowe Price Investment Management, said, \"A lot of bad news has been digested, and the current environment is reminiscent of 2013 and 2018, when the 10-year Treasury Bond yield exceeded 3%. We cut our cash allocation and have been buying US Treasury Bond.\"</p><p>There has been a marked shift in market sentiment over the past two weeks, with investors speculating that the Russia-Ukraine conflict and tightening global monetary policy will drag on economic growth. The 10-year Treasury Bond yield fell 13 basis points to 2.72% on Tuesday, the lowest level since April 27th.<img src=\"https://static.tigerbbs.com/d0a7c3dc21d9e61d01823242de860909\" tg-width=\"550\" tg-height=\"312\" referrerpolicy=\"no-referrer\"/></p><p>The U.S. Treasury Bond market still faces considerable uncertainty, and if the Fed finds itself fighting persistent inflation, then yields could exceed the peak of the past decade. Powell said last week that the Fed was prepared to adjust its policy rate above neutral until there was \"clear and convincing\" evidence that inflation was falling. In addition, the Federal Reserve will also start a shrinking balance sheet from June, which may bring new headwinds to the market.</p><p>Analysts at Goldman Sachs released a rather cautious research report predicting that the 10-year Treasury Bond yield will reach around 3.3% by the end of the year.</p><p>\"We don't think we have reached the point where we can green light the passage,\" said RJ Gallo, senior portfolio manager at Federated Investment. \"The economy still has growth momentum and inflation is not falling rapidly.\"</p><p>However, there are some signals that the Fed's moves are causing the financial environment to tighten. The index of measuring corporate credit risk rises, which makes the borrowing cost of heavily indebted companies rise. Mortgage rates are slowing the housing market, and this year's stock market decline threatens to further erode consumer confidence.</p><p>Yvette Klevan, portfolio manager at Lazard Asset Management's global fixed income team, said \"we're not completely out of the inflation woes, so yields could also rise slightly\". But she added that \"given that a lot of things have been digested, the yield on a 10-year US Treasury Bond should be around 3%\".</p><p>Rick Rieder, chief investment officer of global fixed income at BlackRock, the world's largest asset manager, said that \"several funds have increased their rate exposure more in recent weeks and there are fears that rates will be much higher and we have betted on the other side\".</p><p></body></html></p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Has U.S. debt passed its lowest point? Wall Street veterans decided to take a gamble</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHas U.S. debt passed its lowest point? Wall Street veterans decided to take a gamble\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">环球市场播报</strong><span class=\"h-time small\">2022-05-25 07:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>From<a href=\"https://laohu8.com/S/BLK\">BlackRock</a>By T. Rowe Price Group Inc., some Wall Street veterans experienced in judging bond markets saw signs of re-buying.</p><p>But no one is rushing to judge that the market is bottoming out, because U.S. inflation is still at a four-decade high and the Federal Reserve is just beginning to tighten monetary policy.</p><p>However, U.S. Treasury Bond yields have soared a lot this year, with the 10-year Treasury Bond yield nearly doubling, recalling the proven well-timed buying window at the last ebb. On top of that, there are signs that the economy is cooling, with large retailers reporting changes in consumer spending and declining residential sales. The fall in risky assets such as growth stocks and cryptocurrencies has made the U.S. Treasury Bond a safe haven again, with investors who entered the market to buy when yields peaked earlier this month getting good returns.</p><p>All of this gives long-term fund managers a reason to cautiously increase their exposure, with some prepared to pick up their buying pace when yields exceed what they see as reasonable.<a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Asset Management's global interest rate chief said that the most violent phase of the U.S. debt decline was over, as the prospect of a rate hike by the Federal Reserve was largely absorbed by the market.</p><p>David Giroux, head of Investment strategy at T. Rowe Price Investment Management, said, \"A lot of bad news has been digested, and the current environment is reminiscent of 2013 and 2018, when the 10-year Treasury Bond yield exceeded 3%. We cut our cash allocation and have been buying US Treasury Bond.\"</p><p>There has been a marked shift in market sentiment over the past two weeks, with investors speculating that the Russia-Ukraine conflict and tightening global monetary policy will drag on economic growth. The 10-year Treasury Bond yield fell 13 basis points to 2.72% on Tuesday, the lowest level since April 27th.<img src=\"https://static.tigerbbs.com/d0a7c3dc21d9e61d01823242de860909\" tg-width=\"550\" tg-height=\"312\" referrerpolicy=\"no-referrer\"/></p><p>The U.S. Treasury Bond market still faces considerable uncertainty, and if the Fed finds itself fighting persistent inflation, then yields could exceed the peak of the past decade. Powell said last week that the Fed was prepared to adjust its policy rate above neutral until there was \"clear and convincing\" evidence that inflation was falling. In addition, the Federal Reserve will also start a shrinking balance sheet from June, which may bring new headwinds to the market.</p><p>Analysts at Goldman Sachs released a rather cautious research report predicting that the 10-year Treasury Bond yield will reach around 3.3% by the end of the year.</p><p>\"We don't think we have reached the point where we can green light the passage,\" said RJ Gallo, senior portfolio manager at Federated Investment. \"The economy still has growth momentum and inflation is not falling rapidly.\"</p><p>However, there are some signals that the Fed's moves are causing the financial environment to tighten. The index of measuring corporate credit risk rises, which makes the borrowing cost of heavily indebted companies rise. Mortgage rates are slowing the housing market, and this year's stock market decline threatens to further erode consumer confidence.</p><p>Yvette Klevan, portfolio manager at Lazard Asset Management's global fixed income team, said \"we're not completely out of the inflation woes, so yields could also rise slightly\". But she added that \"given that a lot of things have been digested, the yield on a 10-year US Treasury Bond should be around 3%\".</p><p>Rick Rieder, chief investment officer of global fixed income at BlackRock, the world's largest asset manager, said that \"several funds have increased their rate exposure more in recent weeks and there are fears that rates will be much higher and we have betted on the other side\".</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/stock/usstock/c/2022-05-25/doc-imizirau4597088.shtml?finpagefr=p_115\">环球市场播报</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/d0a7c3dc21d9e61d01823242de860909","relate_stocks":{"IEF":"债券指数ETF-iShares Barclays 7-10年","IEI":"iShares Barclays 3-7 Year Trea","BND":"债券指数ETF-Vanguard美国","TLT":"20+年以上美国国债ETF-iShares","SHY":"债券指数ETF-iShares Barclays 1-3年国债","GOVT":"iShares安硕核心美国国债ETF"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2022-05-25/doc-imizirau4597088.shtml?finpagefr=p_115","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2238371098","content_text":"从贝莱德到T． Rowe Price Group Inc．，华尔街一些对判断债市荣枯颇有经验的市场老手看到了预示可重新买入的迹象。但没有人急着下市场见底的判断，因为美国通胀率仍处于四十年高点，而且美联储刚开始收紧货币政策。但是，今年以来美国国债收益率已经飙升了许多，其中10年期国债收益率上涨近一倍，令人回想起上一次退潮时被证明时机不错的买入窗口。最重要的是，迹象表明经济正在降温， 大型零售商报告消费者支出发生变化，住宅销售下降。成长股、加密货币等风险资产下挫令美国国债再次成为避险天堂，本月早些时候在收益率见顶时入市买入的投资者获得了不错回报。所有这些都让长线基金经理看到了谨慎增加风险敞口的理由，一些人准备在收益率超过他们认为合理的水平时加快买入步伐。摩根大通资产管理的全球利率主管说，美债下跌最猛烈的阶段已经过去，因为美联储的升息前景基本被市场所消化。T． Rowe Price Investment Management投资策略主管David Giroux表示，“很多利空消息已经被消化，现在的环境让人联想到2013年和2018年，当时10年期国债收益率超过3%。 我们削减了现金配置，一直在购买美国国债。”过去两周市场情绪发生了明显转变，投资者猜测俄乌冲突和全球货币政策收紧将拖累经济增长。10年期国债收益率周二盘中一度下挫13基点至2.72%，创4月27日以来最低水平。美国国债市场仍然面临相当大的不确定性，如果美联储发现自己在对抗持续的通胀，那么收益率可能会超过过去十年的峰值。 鲍威尔上周表示，美联储准备将政策利率调整至中性水平以上，直到有“明确且令人信服”的证据表明通胀正在下降。此外，美联储还将从6月开始缩表，这可能给市场带来新的阻力。高盛集团分析师发布了一份颇为谨慎的研报，预测10年期国债收益率将在年末时达到3.3%左右。“我们认为现在还没有达到我们可以绿灯通行的地步，”Federated Investment的高级投资组合经理RJ Gallo表示。“经济仍然有增长动能，通胀率没有迅速下降。”然而，有一些信号显示美联储的举措正在导致金融环境收紧。衡量企业信用风险的指标上升，使得负债累累的公司举债成本上升。抵押贷款利率正在令房地产市场放缓，今年的股市下跌有可能进一步侵蚀消费者信心。Lazard Asset Management全球固定收益团队投资组合经理Yvette Klevan表示，“我们并没有完全摆脱通胀困境，因此收益率还可能略有上升”。但她补充称， “鉴于很多事情已经被消化，10年期美国国债的收益率应该在3%左右”。全球最大资产管理公司贝莱德的全球固定收益业务首席投资官Rick Rieder表示，“几只基金最近几周增加了更多的利率敞口，人们担心利率会高得多，我们已经在另一侧下注”。","news_type":1,"symbols_score_info":{"SHY":0.6,"TLT":0.6,"IEI":0.6,"IEF":0.6,"TNmain":0.6,"BND":1,"UBmain":0.6,"ZTmain":0.6,"GOVT":0.6,"ZFmain":0.6,"ZBmain":0.6}},"isVote":1,"tweetType":1,"viewCount":2853,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9026716183,"gmtCreate":1653435386942,"gmtModify":1676535280138,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026716183","repostId":"2238130573","repostType":4,"isVote":1,"tweetType":1,"viewCount":3380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9062783674,"gmtCreate":1652107518198,"gmtModify":1676535030938,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062783674","repostId":"2234890520","repostType":4,"isVote":1,"tweetType":1,"viewCount":1591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088349179,"gmtCreate":1650322831491,"gmtModify":1676534693717,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088349179","repostId":"613872623","repostType":1,"repost":{"id":613872623,"gmtCreate":1649832120000,"gmtModify":1676532974118,"author":{"id":"3579560926082632","authorId":"3579560926082632","name":"投资界","avatar":"https://static.tigerbbs.com/6a09632062f91283b4308e641ec08979","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579560926082632","idStr":"3579560926082632"},"themes":[],"title":"精“材”路演上线！「创投W+」新材料专场路演顺利举行","htmlText":"4月8日，武漢基金產業基地「創投W+」投融資路演新材料專場順利舉行。本次活動聚焦新材料行業產學研用的深度融合，彙集6個優質項目和多位互動嘉賓線上參與交流和點評，路演項目涉及超級電容器隔膜、生物基“替塑”、AES抗菌抗病毒、高性能電化學水處理等多種新材料，集中展示了新材料領域的優質技術成果和創新應用。 活動前期，我們進行了「創投W+」投融資路演新材料專場活動線上徵集，吸引了來自深創投、鬆禾資本、九鼎投資、青域資本等近20家投資機構的投資人報名參與。會後，基地爲投資人進行了進一步對接，企業與投資人取得了直接聯繫。 活動當天，寧波柔創納米科技有限公司、貴州唯特高新能源科技有限公司、湖北譜萊光電材料有限公司、東部灣（揚州）生物新材料有限公司、浙江楓翎新材料科技有限公司、蘇州碧順環境科技有限公司在此次路演中亮相。6家企業項目各具特色，嘉賓們對項目的營銷策略、資源支持、風險與阻力、發展戰略等方面，提出了專業疑問，項目與機構代表之間形成了良好互動，多個項目獲投資機構青睞。 有項目代表表示，參加本次活動結識了很多投資人，讓他們有機會直接對話資本，探討項目成長路徑，現場思維交流和觀點的碰撞，給企業帶來了創新思考，也讓企業發展更有信心。路演中，武漢的2家本土優質企業受到投資機構的熱切關注，線上提問交流頻繁、會後對接火熱。來自浙江和江蘇的2家路演企業也表明了項目落地的意向。扶持力度大、政策體系全、創新活力足，武漢正以其特有的魅力吸引產業集聚、資本賦能，形成創投活躍的濃厚氛圍。 說到本次產業路演活動的主題，新材料作爲實體經濟的重要內容，是支撐前沿科技及新興產業發展的基石，也是增強產業鏈供應鏈自主可控能力的關鍵。 據統計，2021年我國新材料總產值有望突破7萬億元。預計2025 年新材料產業總產值實現10萬億。回望過去，我國新材料科技領域取得了長足發展，優秀成果層出不窮。國家“雙碳”目標、“卡脖子”","listText":"4月8日，武漢基金產業基地「創投W+」投融資路演新材料專場順利舉行。本次活動聚焦新材料行業產學研用的深度融合，彙集6個優質項目和多位互動嘉賓線上參與交流和點評，路演項目涉及超級電容器隔膜、生物基“替塑”、AES抗菌抗病毒、高性能電化學水處理等多種新材料，集中展示了新材料領域的優質技術成果和創新應用。 活動前期，我們進行了「創投W+」投融資路演新材料專場活動線上徵集，吸引了來自深創投、鬆禾資本、九鼎投資、青域資本等近20家投資機構的投資人報名參與。會後，基地爲投資人進行了進一步對接，企業與投資人取得了直接聯繫。 活動當天，寧波柔創納米科技有限公司、貴州唯特高新能源科技有限公司、湖北譜萊光電材料有限公司、東部灣（揚州）生物新材料有限公司、浙江楓翎新材料科技有限公司、蘇州碧順環境科技有限公司在此次路演中亮相。6家企業項目各具特色，嘉賓們對項目的營銷策略、資源支持、風險與阻力、發展戰略等方面，提出了專業疑問，項目與機構代表之間形成了良好互動，多個項目獲投資機構青睞。 有項目代表表示，參加本次活動結識了很多投資人，讓他們有機會直接對話資本，探討項目成長路徑，現場思維交流和觀點的碰撞，給企業帶來了創新思考，也讓企業發展更有信心。路演中，武漢的2家本土優質企業受到投資機構的熱切關注，線上提問交流頻繁、會後對接火熱。來自浙江和江蘇的2家路演企業也表明了項目落地的意向。扶持力度大、政策體系全、創新活力足，武漢正以其特有的魅力吸引產業集聚、資本賦能，形成創投活躍的濃厚氛圍。 說到本次產業路演活動的主題，新材料作爲實體經濟的重要內容，是支撐前沿科技及新興產業發展的基石，也是增強產業鏈供應鏈自主可控能力的關鍵。 據統計，2021年我國新材料總產值有望突破7萬億元。預計2025 年新材料產業總產值實現10萬億。回望過去，我國新材料科技領域取得了長足發展，優秀成果層出不窮。國家“雙碳”目標、“卡脖子”","text":"4月8日，武漢基金產業基地「創投W+」投融資路演新材料專場順利舉行。本次活動聚焦新材料行業產學研用的深度融合，彙集6個優質項目和多位互動嘉賓線上參與交流和點評，路演項目涉及超級電容器隔膜、生物基“替塑”、AES抗菌抗病毒、高性能電化學水處理等多種新材料，集中展示了新材料領域的優質技術成果和創新應用。 活動前期，我們進行了「創投W+」投融資路演新材料專場活動線上徵集，吸引了來自深創投、鬆禾資本、九鼎投資、青域資本等近20家投資機構的投資人報名參與。會後，基地爲投資人進行了進一步對接，企業與投資人取得了直接聯繫。 活動當天，寧波柔創納米科技有限公司、貴州唯特高新能源科技有限公司、湖北譜萊光電材料有限公司、東部灣（揚州）生物新材料有限公司、浙江楓翎新材料科技有限公司、蘇州碧順環境科技有限公司在此次路演中亮相。6家企業項目各具特色，嘉賓們對項目的營銷策略、資源支持、風險與阻力、發展戰略等方面，提出了專業疑問，項目與機構代表之間形成了良好互動，多個項目獲投資機構青睞。 有項目代表表示，參加本次活動結識了很多投資人，讓他們有機會直接對話資本，探討項目成長路徑，現場思維交流和觀點的碰撞，給企業帶來了創新思考，也讓企業發展更有信心。路演中，武漢的2家本土優質企業受到投資機構的熱切關注，線上提問交流頻繁、會後對接火熱。來自浙江和江蘇的2家路演企業也表明了項目落地的意向。扶持力度大、政策體系全、創新活力足，武漢正以其特有的魅力吸引產業集聚、資本賦能，形成創投活躍的濃厚氛圍。 說到本次產業路演活動的主題，新材料作爲實體經濟的重要內容，是支撐前沿科技及新興產業發展的基石，也是增強產業鏈供應鏈自主可控能力的關鍵。 據統計，2021年我國新材料總產值有望突破7萬億元。預計2025 年新材料產業總產值實現10萬億。回望過去，我國新材料科技領域取得了長足發展，優秀成果層出不窮。國家“雙碳”目標、“卡脖子”","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/613872623","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1580,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"content":"Our efforts will be successful. As long as we persevere, there will be no failure. Come on, everyone","text":"Our efforts will be successful. As long as we persevere, there will be no failure. Come on, everyone","html":"Our efforts will be successful. As long as we persevere, there will be no failure. Come on, everyone"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9014423797,"gmtCreate":1649712832480,"gmtModify":1676534553309,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014423797","repostId":"2226688741","repostType":4,"isVote":1,"tweetType":1,"viewCount":2012,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096782019,"gmtCreate":1644461751143,"gmtModify":1676533929902,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096782019","repostId":"1120878270","repostType":4,"repost":{"id":"1120878270","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644459301,"share":"https://ttm.financial/m/news/1120878270?lang=en_US&edition=fundamental","pubTime":"2022-02-10 10:15","market":"hk","language":"zh","title":"Lepu Biotech starts its IPO today, with an admission fee of HK$7454.38","url":"https://stock-news.laohu8.com/highlight/detail?id=1120878270","media":"老虎资讯综合","summary":"每股发售价介于6.87港元-7.38港元，每手1000股。","content":"<p><html><head></head><body>February 10th news,<a href=\"https://laohu8.com/S/02157\">Lepu Bio-B</a>Announcement: From February 10 to February 15, 2022, the Company intends to issue approximately 127 million shares, of which the Hong Kong Public Offering accounts for 10%, the International Offering accounts for 90%, and the over-allotment option of 15% is attached.<b>Offer price of HK$6.87-HK$7.38 per share, board lot of 1000 shares, admission fee of HK$7454.38</b>Dealings in the Shares on the Stock Exchange are expected to commence on 23 February 2022.</p><p><img src=\"https://static.tigerbbs.com/97e1a27c96f3078f3c0b6f92bab54cb8\" tg-width=\"869\" tg-height=\"610\" referrerpolicy=\"no-referrer\"/></p><p><b>Purchase ladder</b></p><p>Each lot of 1000 shares, the entrance fee is HK$7454.38.</p><p>The threshold of Group B is 70,000 shares, and the funds required for subscription are about HK$ 521,806.55.<img src=\"https://static.tigerbbs.com/64702a21d77baa3223cdcc943a37271a\" tg-width=\"800\" tg-height=\"600\" referrerpolicy=\"no-referrer\"/></p><p><b>Company Profile</b></p><p>Founded in 2018, Lepu Bio has completed three rounds of financing in the past four years, attracting many professional investment funds in the pharmaceutical and medical industry, including Vivo Capital, Suzhou Danqing, SDIC Chuanghe, Ping An Capital, Sunshine Life Insurance, Ronghui Sunshine, Guoxin Central Enterprise, Shanghai Biomedical Fund, etc.</p><p><b>Differentiated layout of PD-1 pan-cancer immunotherapy</b></p><p>Lepu Bio focuses on the combination drug mechanism in the field of tumor therapy, which is<b>The only innovative drug company in China with both PD-1 monoclonal antibodies in the NDA reporting stage and multiple clinical phase II ADC pipelines.</b>There are 8 clinical-stage drug candidates in its product pipeline, mainly composed of targeted therapies (ADC antibody conjugate drugs) and immunotherapy drugs, the latter including two immune checkpoint drugs (PD-1/L1) and one oncolytic virus drug. Three drug candidates have entered registration trials, and two trials are ongoing in the United States. Monoclonal antibody cornerstone products can form combination drug advantages with ADCs, oncolytic viruses, etc. The company will also expand the beneficiary patient population and improve the quality of life of patients.</p><p><img src=\"https://static.tigerbbs.com/893211e958a9d22abefebb7472519142\" tg-width=\"1080\" tg-height=\"606\" referrerpolicy=\"no-referrer\"/></p><p>Source: Prospectus</p><p>The domestic competition for PD-1 (L1) has been extremely fierce, so many companies have begun to target the more cutting-edge therapeutic market. The second indication of PD-1 Putelizumab Injection (HX008), one of the core products of Lepu Bio. The marketing application for MSI-H/dMMR solid tumors was included in the priority review by CDE in November 2021.</p><p>MSI-H/dMMR is the first \"pan-tumor\" tumor marker, and the discovery of MSI-H/dMMR tumor marker has promoted the progress of the tumor treatment approach of \"treating by type regardless of cancer type\". As an emerging immunotherapy biomarker, MSI-H/dMMR has a high detection rate in digestive system cancers such as gastric cancer and colorectal cancer, so it has a wide application prospect. But the competition in the MSI-H/dMMR solid tumor treatment market has just begun. Currently, the global<b>Only three anti-PD- (L) 1 monoclonal antibodies (approved by NMPA), K drug (pembrolizumab, approved by FDA and NMPA), O drug (nivolumab, approved by FDA) and envolizumab, have been approved for the treatment of MSI-H/dMMR solid tumors.</b></p><p>Taking K drug as an example, in a global multicenter large-scale phase III clinical trial of pembrolizumab for the first-line treatment of intestinal cancer, the 3-year survival rate, PFS, ORR, CRR, TRAE and other performances of patients with advanced intestinal cancer using K drug were significantly better than those of patients with advanced intestinal cancer using conventional chemotherapy. The NDA application for HX008 submitted by Lepu Bio has been accepted. HX008 is expected to become the first market product of Lepu Bio and enable patients to benefit from new therapies earlier.</p><p><b>It is also worth mentioning that PD-1 is closest to commercialization in the overall strategic deployment of Lepu Bio and plays an important role. The company will use PD-1 products to open up sales channels, and plans to start marketing in medical institutions and pharmacies after HX008 is approved for the treatment of MSI-H/dMMR solid tumors and melanoma in China, so as to lay the foundation for the smooth listing of ADC products and subsequent pipelines</b>。</p><p><b>Several ADCs are expected to achieve world first</b></p><p>ADC drugs are the core of Lepu Biological's targeted therapy. The company has a variety of targeted ADC drug pipelines, among which the core pipeline HER2 targeted ADC drug MRG002 has the fastest commercialization progress. Lepu Bio has a relatively complete layout in the field of breast cancer treatment, especially one of its core products, MRG002, is a HER2-targeted ADC drug. The HER2 positivity rate in breast cancer is about 25.4%. The second-line progression rate of breast cancer in China is 94.3%.</p><p>Breast cancer is now the most common type of cancer in the world, and the number of new breast cancer cases in China reached 331,600 in 2020. According to Frost & Sullivan, the size of the breast cancer market in China was RMB50.7 billion in 2020 and is expected to reach RMB81.8 billion and RMB124.6 billion by 2025 and 2030, respectively.</p><p>MRG002 has achieved a breakthrough in phase II clinical studies. This Phase II clinical trial was led by Professor Jiang Zefei of the People's Liberation Army General Hospital, who gave a detailed report in the special session on innovative drug clinical research data at the CSCO Annual Meeting in September 2021. Jiang Zefei said that the innovative efficacy of MRG002 comes from its innovative molecular design, because ADC drug design has unique difficulties in cytotoxicity and linkers.</p><p>There has never been a shortage of blockbuster varieties in the global breast cancer treatment market. According to Nature Reviews Drug Discovery, the global sales of ADCs currently on the market will exceed $16.4 billion in 2026.</p><p>Another core pipeline, MRG003, is an EGFR-targeted ADC drug candidate. According to Frost & Sullivan, MRG003 is currently<b>Domestic first and international clinical progress leading</b>For ADC drugs targeting EGFR, worldwide, except Japan's Rakuten Medical's product Akalux (suitable for irresectable locally recurrent head and neck cancer), which has been approved by PMDA, no other ADC targeting EGFR has been approved. Lepu Bio is conducting a number of phase II clinical trials for MRG003 in China.</p><p>Similarly, other ADC pipelines also have the potential to be first of its kind. For example, CMG901 jointly developed by Lepu Bio and Connoya (2162.HK) is the world's first CLDN18.2-targeted ADC approved by IND; The company's self-developed MRG001 is aimed at hematological tumors. There is currently no approved CD20-targeted ADC product in the world. The only CD20-targeted ADCs in the clinical stage in China are the company's MRG001 and Territh's TRS005.</p><p><b>ADC drug technology is complex, and many pipelines will face the challenge of early R&D failure; In addition, for ADC drugs to be finally approved for marketing, the company's ADC commercial production capacity and production experience are also crucial.</b>Dr. Hu Chaohong, co-general manager of Lepu Bio, has worked at Seagen (SGEN.US) for many years, and the team has rich experience in ADC drug development. Lepu Bio also has a clinically proven ADC platform for coupling and CMC technologies, as well as a development and analysis platform for advanced processes as support for commercial production.</p><p><b>Clinical progress of oncolytic virus leads the world</b></p><p>Lepu Bio introduced the innovative pipeline CG0070 from CG Oncology and obtained the right to develop, manufacture and commercialize the product in China. The company has submitted an IND application to the State Food and Drug Administration for intravesical administration of CG0070 for the treatment of bladder cancer (NMIBC, non-muscle invasive bladder cancer that does not respond to BCG) and other solid tumors.<b>The application for NMIBC has been clinically approved by CDE,</b>Conduct clinical trials for this indication.</p><p>According to Frost & Sullivan,<b>CG0070 is the first and only oncolytic adenovirus in clinical development for bladder cancer</b>。 Oncolytic viruses are a class of viruses that can selectively lyse cancer cells. On the one hand, they can infect tumor cells and cause cell lysis; On the other hand, the molecules they release during lysis can also induce innate and adaptive immune responses, attracting more immune cells to continue to kill residual tumor cells, so oncolytic viruses have good clinical prospects as innovative therapies.</p><p>The main indication of oncolytic virus is bladder cancer, which is the most common malignant tumor of the urinary system and has the highest incidence of urogenital tract tumors in China.<b>With a five-year survival rate of 72.9% in China, there are significant market opportunities for bladder cancer treatment.</b>In addition, the oncolytic virus can also be expanded to other indications, especially in combination,<b>The combination of oncolytic virus and anti-PD-1/anti-PD-L1 monoclonal antibodies has emerged as an emerging treatment for advanced malignancies.</b></p><p>CG0070 has shown good safety and efficacy in the Phase II clinical study conducted by CG Oncology in the United States for the treatment of NMIBC. On November 13, 2021, CG Oncology disclosed the very eye-catching Phase II clinical trial data of CG0070 combined with K drug.<b>The trial results showed that among the 9 NMIBC patients with evaluable efficacy, all patients achieved complete response (CR) at 3 months. In addition, the CR rate of patients who reached the 6-month evaluation node and the 9-month evaluation node was also maintained 100%.</b></p><p>Many companies around the world have laid out a total of more than 180 oncolytic virus pipelines, but at present, CG Oncology and Candel Therapeutics (CADL.US)' aglatimagene besadenovec (which has entered clinical phase III for the treatment of prostate cancer) are among the faster-progressing pipelines.</p><p>In addition to CG0070, Lepu Bio also has a stake in Wuhan Binhui Bio, which independently developed recombinant human GM-CSF oncolytic type II herpes simplex virus (OH2) injection. The prospectus of Lepu Bio shows that the combination therapy of HX008 combined with OH2 for advanced hepatocellular carcinoma has been approved for IND and the corresponding phase I clinical trial has started.</p><p>Lepu Bio has established multiple tumor treatment pipelines for multiple indications. As product commercialization approaches, the company is also promoting research on the combination of monoclonal antibodies with other core pipelines, with a view to providing patients with innovative and even disruptive treatment options. In addition to the above HX008 combined with OH2, Lepu Bio also plans to develop ADC combined with HX008 for the treatment of advanced head and neck squamous cell carcinoma (HNSCC). MRG003 in combination with HX008 for HNSCC and MRG002 in combination with HX008 for gastric cancer have received IND approval from the NMPA.</p><p>From a global perspective, in clinical trials of monoclonal antibody products such as K drugs combined with ADCs and oncolytic viruses, combination therapy generally shows a higher complete remission rate than single drugs, and the survival rate of patients participating in combination chemotherapy trials is also improving.</p><p>While advancing the development of product candidates, the company has planned and is implementing the production and commercialization layout. In 2019, Lepu Bio built and put into production a GMP-standard 2,000L antibody production line in Beijing, and is currently building a 200L oncolytic virus drug production line in Beijing. At present, the company is also building a biomedical production center in Shanghai, including the construction of a production line with a preliminary designed capacity of 12,000L and supporting laboratories and factories. Relying on the company's team and technology platform, the construction of production and commercialization capabilities will also provide great support for the company's global layout.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lepu Biotech starts its IPO today, with an admission fee of HK$7454.38</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLepu Biotech starts its IPO today, with an admission fee of HK$7454.38\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2022-02-10 10:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>February 10th news,<a href=\"https://laohu8.com/S/02157\">Lepu Bio-B</a>Announcement: From February 10 to February 15, 2022, the Company intends to issue approximately 127 million shares, of which the Hong Kong Public Offering accounts for 10%, the International Offering accounts for 90%, and the over-allotment option of 15% is attached.<b>Offer price of HK$6.87-HK$7.38 per share, board lot of 1000 shares, admission fee of HK$7454.38</b>Dealings in the Shares on the Stock Exchange are expected to commence on 23 February 2022.</p><p><img src=\"https://static.tigerbbs.com/97e1a27c96f3078f3c0b6f92bab54cb8\" tg-width=\"869\" tg-height=\"610\" referrerpolicy=\"no-referrer\"/></p><p><b>Purchase ladder</b></p><p>Each lot of 1000 shares, the entrance fee is HK$7454.38.</p><p>The threshold of Group B is 70,000 shares, and the funds required for subscription are about HK$ 521,806.55.<img src=\"https://static.tigerbbs.com/64702a21d77baa3223cdcc943a37271a\" tg-width=\"800\" tg-height=\"600\" referrerpolicy=\"no-referrer\"/></p><p><b>Company Profile</b></p><p>Founded in 2018, Lepu Bio has completed three rounds of financing in the past four years, attracting many professional investment funds in the pharmaceutical and medical industry, including Vivo Capital, Suzhou Danqing, SDIC Chuanghe, Ping An Capital, Sunshine Life Insurance, Ronghui Sunshine, Guoxin Central Enterprise, Shanghai Biomedical Fund, etc.</p><p><b>Differentiated layout of PD-1 pan-cancer immunotherapy</b></p><p>Lepu Bio focuses on the combination drug mechanism in the field of tumor therapy, which is<b>The only innovative drug company in China with both PD-1 monoclonal antibodies in the NDA reporting stage and multiple clinical phase II ADC pipelines.</b>There are 8 clinical-stage drug candidates in its product pipeline, mainly composed of targeted therapies (ADC antibody conjugate drugs) and immunotherapy drugs, the latter including two immune checkpoint drugs (PD-1/L1) and one oncolytic virus drug. Three drug candidates have entered registration trials, and two trials are ongoing in the United States. Monoclonal antibody cornerstone products can form combination drug advantages with ADCs, oncolytic viruses, etc. The company will also expand the beneficiary patient population and improve the quality of life of patients.</p><p><img src=\"https://static.tigerbbs.com/893211e958a9d22abefebb7472519142\" tg-width=\"1080\" tg-height=\"606\" referrerpolicy=\"no-referrer\"/></p><p>Source: Prospectus</p><p>The domestic competition for PD-1 (L1) has been extremely fierce, so many companies have begun to target the more cutting-edge therapeutic market. The second indication of PD-1 Putelizumab Injection (HX008), one of the core products of Lepu Bio. The marketing application for MSI-H/dMMR solid tumors was included in the priority review by CDE in November 2021.</p><p>MSI-H/dMMR is the first \"pan-tumor\" tumor marker, and the discovery of MSI-H/dMMR tumor marker has promoted the progress of the tumor treatment approach of \"treating by type regardless of cancer type\". As an emerging immunotherapy biomarker, MSI-H/dMMR has a high detection rate in digestive system cancers such as gastric cancer and colorectal cancer, so it has a wide application prospect. But the competition in the MSI-H/dMMR solid tumor treatment market has just begun. Currently, the global<b>Only three anti-PD- (L) 1 monoclonal antibodies (approved by NMPA), K drug (pembrolizumab, approved by FDA and NMPA), O drug (nivolumab, approved by FDA) and envolizumab, have been approved for the treatment of MSI-H/dMMR solid tumors.</b></p><p>Taking K drug as an example, in a global multicenter large-scale phase III clinical trial of pembrolizumab for the first-line treatment of intestinal cancer, the 3-year survival rate, PFS, ORR, CRR, TRAE and other performances of patients with advanced intestinal cancer using K drug were significantly better than those of patients with advanced intestinal cancer using conventional chemotherapy. The NDA application for HX008 submitted by Lepu Bio has been accepted. HX008 is expected to become the first market product of Lepu Bio and enable patients to benefit from new therapies earlier.</p><p><b>It is also worth mentioning that PD-1 is closest to commercialization in the overall strategic deployment of Lepu Bio and plays an important role. The company will use PD-1 products to open up sales channels, and plans to start marketing in medical institutions and pharmacies after HX008 is approved for the treatment of MSI-H/dMMR solid tumors and melanoma in China, so as to lay the foundation for the smooth listing of ADC products and subsequent pipelines</b>。</p><p><b>Several ADCs are expected to achieve world first</b></p><p>ADC drugs are the core of Lepu Biological's targeted therapy. The company has a variety of targeted ADC drug pipelines, among which the core pipeline HER2 targeted ADC drug MRG002 has the fastest commercialization progress. Lepu Bio has a relatively complete layout in the field of breast cancer treatment, especially one of its core products, MRG002, is a HER2-targeted ADC drug. The HER2 positivity rate in breast cancer is about 25.4%. The second-line progression rate of breast cancer in China is 94.3%.</p><p>Breast cancer is now the most common type of cancer in the world, and the number of new breast cancer cases in China reached 331,600 in 2020. According to Frost & Sullivan, the size of the breast cancer market in China was RMB50.7 billion in 2020 and is expected to reach RMB81.8 billion and RMB124.6 billion by 2025 and 2030, respectively.</p><p>MRG002 has achieved a breakthrough in phase II clinical studies. This Phase II clinical trial was led by Professor Jiang Zefei of the People's Liberation Army General Hospital, who gave a detailed report in the special session on innovative drug clinical research data at the CSCO Annual Meeting in September 2021. Jiang Zefei said that the innovative efficacy of MRG002 comes from its innovative molecular design, because ADC drug design has unique difficulties in cytotoxicity and linkers.</p><p>There has never been a shortage of blockbuster varieties in the global breast cancer treatment market. According to Nature Reviews Drug Discovery, the global sales of ADCs currently on the market will exceed $16.4 billion in 2026.</p><p>Another core pipeline, MRG003, is an EGFR-targeted ADC drug candidate. According to Frost & Sullivan, MRG003 is currently<b>Domestic first and international clinical progress leading</b>For ADC drugs targeting EGFR, worldwide, except Japan's Rakuten Medical's product Akalux (suitable for irresectable locally recurrent head and neck cancer), which has been approved by PMDA, no other ADC targeting EGFR has been approved. Lepu Bio is conducting a number of phase II clinical trials for MRG003 in China.</p><p>Similarly, other ADC pipelines also have the potential to be first of its kind. For example, CMG901 jointly developed by Lepu Bio and Connoya (2162.HK) is the world's first CLDN18.2-targeted ADC approved by IND; The company's self-developed MRG001 is aimed at hematological tumors. There is currently no approved CD20-targeted ADC product in the world. The only CD20-targeted ADCs in the clinical stage in China are the company's MRG001 and Territh's TRS005.</p><p><b>ADC drug technology is complex, and many pipelines will face the challenge of early R&D failure; In addition, for ADC drugs to be finally approved for marketing, the company's ADC commercial production capacity and production experience are also crucial.</b>Dr. Hu Chaohong, co-general manager of Lepu Bio, has worked at Seagen (SGEN.US) for many years, and the team has rich experience in ADC drug development. Lepu Bio also has a clinically proven ADC platform for coupling and CMC technologies, as well as a development and analysis platform for advanced processes as support for commercial production.</p><p><b>Clinical progress of oncolytic virus leads the world</b></p><p>Lepu Bio introduced the innovative pipeline CG0070 from CG Oncology and obtained the right to develop, manufacture and commercialize the product in China. The company has submitted an IND application to the State Food and Drug Administration for intravesical administration of CG0070 for the treatment of bladder cancer (NMIBC, non-muscle invasive bladder cancer that does not respond to BCG) and other solid tumors.<b>The application for NMIBC has been clinically approved by CDE,</b>Conduct clinical trials for this indication.</p><p>According to Frost & Sullivan,<b>CG0070 is the first and only oncolytic adenovirus in clinical development for bladder cancer</b>。 Oncolytic viruses are a class of viruses that can selectively lyse cancer cells. On the one hand, they can infect tumor cells and cause cell lysis; On the other hand, the molecules they release during lysis can also induce innate and adaptive immune responses, attracting more immune cells to continue to kill residual tumor cells, so oncolytic viruses have good clinical prospects as innovative therapies.</p><p>The main indication of oncolytic virus is bladder cancer, which is the most common malignant tumor of the urinary system and has the highest incidence of urogenital tract tumors in China.<b>With a five-year survival rate of 72.9% in China, there are significant market opportunities for bladder cancer treatment.</b>In addition, the oncolytic virus can also be expanded to other indications, especially in combination,<b>The combination of oncolytic virus and anti-PD-1/anti-PD-L1 monoclonal antibodies has emerged as an emerging treatment for advanced malignancies.</b></p><p>CG0070 has shown good safety and efficacy in the Phase II clinical study conducted by CG Oncology in the United States for the treatment of NMIBC. On November 13, 2021, CG Oncology disclosed the very eye-catching Phase II clinical trial data of CG0070 combined with K drug.<b>The trial results showed that among the 9 NMIBC patients with evaluable efficacy, all patients achieved complete response (CR) at 3 months. In addition, the CR rate of patients who reached the 6-month evaluation node and the 9-month evaluation node was also maintained 100%.</b></p><p>Many companies around the world have laid out a total of more than 180 oncolytic virus pipelines, but at present, CG Oncology and Candel Therapeutics (CADL.US)' aglatimagene besadenovec (which has entered clinical phase III for the treatment of prostate cancer) are among the faster-progressing pipelines.</p><p>In addition to CG0070, Lepu Bio also has a stake in Wuhan Binhui Bio, which independently developed recombinant human GM-CSF oncolytic type II herpes simplex virus (OH2) injection. The prospectus of Lepu Bio shows that the combination therapy of HX008 combined with OH2 for advanced hepatocellular carcinoma has been approved for IND and the corresponding phase I clinical trial has started.</p><p>Lepu Bio has established multiple tumor treatment pipelines for multiple indications. As product commercialization approaches, the company is also promoting research on the combination of monoclonal antibodies with other core pipelines, with a view to providing patients with innovative and even disruptive treatment options. In addition to the above HX008 combined with OH2, Lepu Bio also plans to develop ADC combined with HX008 for the treatment of advanced head and neck squamous cell carcinoma (HNSCC). MRG003 in combination with HX008 for HNSCC and MRG002 in combination with HX008 for gastric cancer have received IND approval from the NMPA.</p><p>From a global perspective, in clinical trials of monoclonal antibody products such as K drugs combined with ADCs and oncolytic viruses, combination therapy generally shows a higher complete remission rate than single drugs, and the survival rate of patients participating in combination chemotherapy trials is also improving.</p><p>While advancing the development of product candidates, the company has planned and is implementing the production and commercialization layout. In 2019, Lepu Bio built and put into production a GMP-standard 2,000L antibody production line in Beijing, and is currently building a 200L oncolytic virus drug production line in Beijing. At present, the company is also building a biomedical production center in Shanghai, including the construction of a production line with a preliminary designed capacity of 12,000L and supporting laboratories and factories. Relying on the company's team and technology platform, the construction of production and commercialization capabilities will also provide great support for the company's global layout.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c8d9586192423abb2922de7db5c64252","relate_stocks":{"02157":"乐普生物-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120878270","content_text":"2月10日消息，乐普生物-B公告：于2022年2月10日-2月15日进行招股，公司拟发行约1.27亿股，其中香港公开发售占10%，国际发售占90%，另附有15%的超额配股权。每股发售价为6.87港元-7.38港元，每手1000股，入场费7454.38港元，预期股份将于2022年2月23日在联交所开始买卖。申购阶梯每手1000股，入场费7454.38港元。乙组门槛为70000股，申购所需资金约521806.55港元。公司简介乐普生物成立于2018年，近4年一共完成了3轮融资，吸引了众多专业的医药医疗行业投资基金，包括维梧资本、苏州丹青、国投创合、平安资本、阳光人寿、融汇阳光、国新央企、上海生物医药基金等。差异化布局PD-1泛癌种免疫治疗乐普生物聚焦肿瘤治疗领域的联合用药机制，是国内唯一一家既有NDA报产阶段PD-1单抗，又拥有多个临床II期ADC管线的创新药企业。其产品管线中有8种临床阶段候选药物，主要由靶向疗法（ADC抗体偶联药物）和免疫治疗药物构成，后者包括两种免疫检查点药物（PD-1/L1）和一种溶瘤病毒药物。三项候选药物已进入注册性试验，两项试验正在美国进行。单抗类基石产品与ADC、溶瘤病毒等可形成联合用药优势，公司也将扩大受益患者群，提高患者的生存质量。来源：招股书PD-1（L1）在国内竞争已经异常激烈，因此不少企业都开始瞄准更前沿的治疗市场，乐普生物核心产品之一PD-1 普特利单抗注射液（HX008）第二个适应症MSI-H/dMMR 实体瘤的上市申请，2021年11月被CDE纳入优先评审。MSI-H/dMMR是第一个「泛瘤种」肿瘤标志物，MSI-H/dMMR肿瘤标志物的发现推动了「不分癌种，分型而治」的肿瘤治疗方式的进展。作为新兴的免疫治疗生物标志物，MSI-H/dMMR在胃癌、结直肠癌等消化系统癌症中的检出率较高，因此具有广泛的应用前景。但MSI-H/dMMR实体瘤治疗市场的竞争才刚开始。目前，全球仅获批了K药（帕博丽珠单抗，已于FDA、NMPA获批）、O药（纳武利尤单抗，已于FDA获批）及恩沃利单抗3款抗PD-(L)1单抗（已于NMPA获批）用于治疗MSI-H/dMMR实体瘤。以K药为例，在帕博利珠单抗针对肠癌一线治疗的全球多中心的大型III期临床试验中，使用K药的晚期肠癌患者的3年生存率、PFS、ORR、CRR、TRAE等表现都明显优于使用常规化疗的晚期肠癌患者。乐普生物提交的HX008的NDA申请已获受理，HX008有望成为乐普生物首个上市产品，并使患者较早从新疗法中获益。另外值得一提的是，PD-1在乐普生物整体战略部署中离商业化最近，具有重要地位。公司将借助PD-1产品来打通销售渠道，计划HX008国内获批用于治疗MSI-H/dMMR实体瘤及黑色素瘤后启动在医疗机构、药房体系的营销工作，为ADC产品及后续管线顺利上市奠定基础。多款ADC有望实现全球首创ADC药物是乐普生物靶向疗法的核心，公司拥有多种靶向ADC药物管线，其中核心管线HER2靶向ADC药物MRG002商业化进展最快。乐普生物在乳腺癌治疗领域有相对完善的布局，尤其是核心产品之一MRG002为HER2靶向ADC药物。乳腺癌的HER2阳性率约为25.4%。中国乳腺癌的二线进展率为94.3%。乳腺癌现成为全球最常见的癌种，中国2020年新增的乳腺癌病例数达到33.16万。据弗若斯特沙利文的资料，2020年中国乳腺癌市场的规模为人民币507亿元，预计至2025年及2030年将分别达到818亿元及1246亿元。MRG002在II期临床研究中已实现突破。此II期临床试验由解放军总医院江泽飞教授牵头，江泽飞在2021年9月的CSCO年会创新药物临床研究数据专场中作了详细汇报。江泽飞表示，MRG002的创新疗效来自于其创新的分子设计，因为ADC药物设计在细胞毒、连接子方面都有独特难点。全球的乳腺癌治疗市场从来不乏重磅品种。据Nature Reviews Drug Discovery预计，2026年，目前已上市ADC的全球销售额将超过164亿美元。另一项核心管线MRG003为一款EGFR靶向ADC候选药物。据弗若斯特沙利文，MRG003是目前国内首创和国际临床进度领先的靶向EGFR的ADC药物，全球范围内，除了日本Rakuten Medical的产品Akalux（适用于不能切除的局部复发性头颈癌）获PMDA批准外，还没有其他靶向EGFR的ADC获批。乐普生物正在就MRG003在中国进行多项II期临床试验。同样，ADC其他管线也具有同类首创的潜质。例如，乐普生物与康诺亚（2162.HK）合作开发的CMG901是全球首款获IND批准的CLDN18.2靶向ADC；公司自研的MRG001针对血液肿瘤，全球目前尚未有获批的CD20靶向ADC产品，国内进入临床阶段的CD20靶向ADC仅有公司的MRG001和特瑞思的TRS005。ADC药物技术复杂，很多管线会面临前期研发失败的挑战；此外，ADC药物能最终获批上市，企业的ADC商业化生产能力、生产经验也至关重要。乐普生物联席总经理胡朝红博士在Seagen（SGEN.US）工作多年，团队拥有丰富的ADC药物研发经验。乐普生物也具有经临床验证的偶联和CMC技术的ADC平台，以及先进工艺的开发分析平台作为商业化生产的支持。溶瘤病毒临床进展全球领先乐普生物从CG Oncology引进了创新型管线CG0070，获得了该产品在国内的开发、制造和商业化权利。公司已向国家药监局提交CG0070膀胱内给药治疗膀胱癌（NMIBC，即卡介苗（BCG）无应答的非肌层浸润性膀胱癌）及其他实体瘤的IND申请，针对NMIBC的申请已获CDE的临床批件，开展对该适应症的临床试验。据弗若斯特沙利文，CG0070是首个也是唯一一个处于临床开发阶段的治疗膀胱癌的溶瘤腺病毒。溶瘤病毒是一类能选择性裂解癌细胞的病毒，一方面，它们可以感染肿瘤细胞并引起细胞裂解；另一方面，它们在裂解过程中释放的分子还能诱导先天性和适应性免疫反应，吸引更多免疫细胞来继续杀死残余肿瘤细胞，因此溶瘤病毒作为创新疗法有很好的临床前景。溶瘤病毒的主要适应症为膀胱癌，膀胱癌是泌尿系统最常见的恶性肿瘤，在中国泌尿生殖道肿瘤的发病率最高，在中国的五年生存率为72.9%，膀胱癌治疗有重大的市场机会。此外，溶瘤病毒还可拓展至其他适应症，尤其能在联用中体现优势，溶瘤病毒及抗PD-1╱抗PD-L1单克隆抗体的联合已成为新兴的晚期恶性肿瘤治疗方法。CG0070在CG Oncology于美国进行的用于治疗NMIBC的临床II期研究中展现出良好的安全性及疗效， 2021年11月13日，CG Oncology披露了CG0070联合K药十分亮眼的Ⅱ期临床试验数据。试验结果显示，在可评估疗效的9名NMIBC患者中，所有患者在3个月时实现了完全缓解（CR），此外，达到6个月评估节点和9个月评估节点的患者CR率也保持了100%。全球很多家企业布局了共约180多款溶瘤病毒管线，但目前CG Oncology和美国Candel Therapeutics（CADL.US）的aglatimagene besadenovec（治疗前列腺癌进入了临床III期）属于其中进展较快的管线。除CG0070外，乐普生物还参股了武汉滨会生物，滨会生物自主开发了重组人GM-CSF溶瘤II型单纯疱疹病毒（OH2）注射液。乐普生物招股书显示，HX008联合OH2针对晚期肝细胞癌的联合疗法已经获批IND并开始相应的I期临床试验。乐普生物已建立起针对多种适应症的多个肿瘤治疗管线。随着产品商业化的临近，公司也在推进单抗与其他核心管线联用的研究，以期为患者提供创新甚至颠覆性的治疗方案。除上述HX008联合OH2外，乐普生物还计划就ADC联合HX008治疗晚期头颈部鳞状细胞癌（HNSCC）等进行研发。MRG003联合HX008治疗HNSCC，以及MRG002与HX008联合治疗胃癌均已从国家药监局获得了IND批准。而从全球来看，K药等单抗产品与ADC、溶瘤病毒联用的临床试验中，联合疗法普遍显示出较单药更高的完全缓解率，参与联合化疗试验的患者生存率也在提高。在推进候选产品开发的同时，公司已规划并正在落实生产和商业化布局。2019年，乐普生物在北京建设了GMP标准的2,000L抗体生产线并投产，目前还正在北京建设200L溶瘤病毒药物生产线。公司目前还在建上海的生物医药生产中心，包括初步设计产能12,000L的生产线及配套实验室和厂房的建设。依托公司的团队和技术平台，生产及商业化能力的建设也将为公司的全球化布局提供巨大支持。","news_type":1,"symbols_score_info":{"02157":0.9}},"isVote":1,"tweetType":1,"viewCount":1769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096940559,"gmtCreate":1644287131714,"gmtModify":1676533908888,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096940559","repostId":"1162467337","repostType":4,"isVote":1,"tweetType":1,"viewCount":1393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096039914,"gmtCreate":1644248676565,"gmtModify":1676533904606,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096039914","repostId":"2209371501","repostType":4,"isVote":1,"tweetType":1,"viewCount":1565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002709235,"gmtCreate":1642085374154,"gmtModify":1676533679368,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002709235","repostId":"2203762528","repostType":2,"isVote":1,"tweetType":1,"viewCount":1462,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002709386,"gmtCreate":1642085334551,"gmtModify":1676533679367,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002709386","repostId":"2203762528","repostType":4,"isVote":1,"tweetType":1,"viewCount":1559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002453972,"gmtCreate":1642078847446,"gmtModify":1676533678512,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002453972","repostId":"2203763141","repostType":4,"isVote":1,"tweetType":1,"viewCount":1092,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002336586,"gmtCreate":1641912971493,"gmtModify":1676533661202,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002336586","repostId":"2202204160","repostType":4,"isVote":1,"tweetType":1,"viewCount":1878,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":814456542,"gmtCreate":1630880986086,"gmtModify":1676530408196,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good day&nbsp;","listText":"Good day&nbsp;","text":"Good day","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/814456542","repostId":"1152020609","repostType":4,"repost":{"id":"1152020609","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630572749,"share":"https://ttm.financial/m/news/1152020609?lang=en_US&edition=fundamental","pubTime":"2021-09-02 16:52","market":"us","language":"zh","title":"Reminder: U.S. stocks are closed for one day on September 6th due to Labor Day in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=1152020609","media":"老虎资讯综合","summary":"9月6日（下周一），美国股市因劳工节休市一天，9月7日（下周二）起恢复交易。\n港股、A股、英股、澳股、新加坡股市照常交易。\n背景简介：\n九月的第一个星期一是美国的劳工节（Labor Day），在189","content":"<p>On September 6th (next Monday), the U.S. stock market will be closed for one day for Labor Day, and trading will resume from September 7th (next Tuesday).</p><p>Hong Kong shares, A shares, British shares, Australian shares and Singapore stock markets traded as usual.</p><p><b>Background Introduction:</b></p><p>The first Monday in September is Labor Day in the United States, which was established as a national holiday in the United States, Labor Day in the United States in 1894.</p><p>On this day, people all over the United States usually hold *, rallies and other celebrations to show respect for labor. In some states, people have picnics after *, eating, drinking, singing and dancing. At night, fireworks will be set off in some places.</p><p><img src=\"https://static.tigerbbs.com/6a3b13247eca5b02ef7724259aead09e\" tg-width=\"800\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: U.S. stocks are closed for one day on September 6th due to Labor Day in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: U.S. stocks are closed for one day on September 6th due to Labor Day in the United States\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-02 16:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On September 6th (next Monday), the U.S. stock market will be closed for one day for Labor Day, and trading will resume from September 7th (next Tuesday).</p><p>Hong Kong shares, A shares, British shares, Australian shares and Singapore stock markets traded as usual.</p><p><b>Background Introduction:</b></p><p>The first Monday in September is Labor Day in the United States, which was established as a national holiday in the United States, Labor Day in the United States in 1894.</p><p>On this day, people all over the United States usually hold *, rallies and other celebrations to show respect for labor. In some states, people have picnics after *, eating, drinking, singing and dancing. At night, fireworks will be set off in some places.</p><p><img src=\"https://static.tigerbbs.com/6a3b13247eca5b02ef7724259aead09e\" tg-width=\"800\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6a3b13247eca5b02ef7724259aead09e","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152020609","content_text":"9月6日（下周一），美国股市因劳工节休市一天，9月7日（下周二）起恢复交易。\n港股、A股、英股、澳股、新加坡股市照常交易。\n背景简介：\n九月的第一个星期一是美国的劳工节（Labor Day），在1894年被确立为美国的国家节日，即美国的劳动节。\n这一天，全美各地民众一般都会举行游行、集会等各种庆祝活动，以示对劳工的尊重。在一些州，人们在游行之后还要举办野餐会，热闹地吃喝、唱歌、跳舞。入夜，有的地方还会放焰火。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":250806779003056,"gmtCreate":1702251264994,"gmtModify":1702251269072,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good job and do it better&nbsp;","listText":"Good job and do it better&nbsp;","text":"Good job and do it better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/250806779003056","isVote":1,"tweetType":1,"viewCount":4386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934222915,"gmtCreate":1663260376337,"gmtModify":1676537239022,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9934222915","repostId":"2267687636","repostType":4,"isVote":1,"tweetType":1,"viewCount":4178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9026712553,"gmtCreate":1653435450372,"gmtModify":1676535280170,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026712553","repostId":"2238304789","repostType":4,"isVote":1,"tweetType":1,"viewCount":4030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088349179,"gmtCreate":1650322831491,"gmtModify":1676534693717,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088349179","repostId":"613872623","repostType":1,"repost":{"id":613872623,"gmtCreate":1649832120000,"gmtModify":1676532974118,"author":{"id":"3579560926082632","authorId":"3579560926082632","name":"投资界","avatar":"https://static.tigerbbs.com/6a09632062f91283b4308e641ec08979","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579560926082632","idStr":"3579560926082632"},"themes":[],"title":"精“材”路演上线！「创投W+」新材料专场路演顺利举行","htmlText":"4月8日，武漢基金產業基地「創投W+」投融資路演新材料專場順利舉行。本次活動聚焦新材料行業產學研用的深度融合，彙集6個優質項目和多位互動嘉賓線上參與交流和點評，路演項目涉及超級電容器隔膜、生物基“替塑”、AES抗菌抗病毒、高性能電化學水處理等多種新材料，集中展示了新材料領域的優質技術成果和創新應用。 活動前期，我們進行了「創投W+」投融資路演新材料專場活動線上徵集，吸引了來自深創投、鬆禾資本、九鼎投資、青域資本等近20家投資機構的投資人報名參與。會後，基地爲投資人進行了進一步對接，企業與投資人取得了直接聯繫。 活動當天，寧波柔創納米科技有限公司、貴州唯特高新能源科技有限公司、湖北譜萊光電材料有限公司、東部灣（揚州）生物新材料有限公司、浙江楓翎新材料科技有限公司、蘇州碧順環境科技有限公司在此次路演中亮相。6家企業項目各具特色，嘉賓們對項目的營銷策略、資源支持、風險與阻力、發展戰略等方面，提出了專業疑問，項目與機構代表之間形成了良好互動，多個項目獲投資機構青睞。 有項目代表表示，參加本次活動結識了很多投資人，讓他們有機會直接對話資本，探討項目成長路徑，現場思維交流和觀點的碰撞，給企業帶來了創新思考，也讓企業發展更有信心。路演中，武漢的2家本土優質企業受到投資機構的熱切關注，線上提問交流頻繁、會後對接火熱。來自浙江和江蘇的2家路演企業也表明了項目落地的意向。扶持力度大、政策體系全、創新活力足，武漢正以其特有的魅力吸引產業集聚、資本賦能，形成創投活躍的濃厚氛圍。 說到本次產業路演活動的主題，新材料作爲實體經濟的重要內容，是支撐前沿科技及新興產業發展的基石，也是增強產業鏈供應鏈自主可控能力的關鍵。 據統計，2021年我國新材料總產值有望突破7萬億元。預計2025 年新材料產業總產值實現10萬億。回望過去，我國新材料科技領域取得了長足發展，優秀成果層出不窮。國家“雙碳”目標、“卡脖子”","listText":"4月8日，武漢基金產業基地「創投W+」投融資路演新材料專場順利舉行。本次活動聚焦新材料行業產學研用的深度融合，彙集6個優質項目和多位互動嘉賓線上參與交流和點評，路演項目涉及超級電容器隔膜、生物基“替塑”、AES抗菌抗病毒、高性能電化學水處理等多種新材料，集中展示了新材料領域的優質技術成果和創新應用。 活動前期，我們進行了「創投W+」投融資路演新材料專場活動線上徵集，吸引了來自深創投、鬆禾資本、九鼎投資、青域資本等近20家投資機構的投資人報名參與。會後，基地爲投資人進行了進一步對接，企業與投資人取得了直接聯繫。 活動當天，寧波柔創納米科技有限公司、貴州唯特高新能源科技有限公司、湖北譜萊光電材料有限公司、東部灣（揚州）生物新材料有限公司、浙江楓翎新材料科技有限公司、蘇州碧順環境科技有限公司在此次路演中亮相。6家企業項目各具特色，嘉賓們對項目的營銷策略、資源支持、風險與阻力、發展戰略等方面，提出了專業疑問，項目與機構代表之間形成了良好互動，多個項目獲投資機構青睞。 有項目代表表示，參加本次活動結識了很多投資人，讓他們有機會直接對話資本，探討項目成長路徑，現場思維交流和觀點的碰撞，給企業帶來了創新思考，也讓企業發展更有信心。路演中，武漢的2家本土優質企業受到投資機構的熱切關注，線上提問交流頻繁、會後對接火熱。來自浙江和江蘇的2家路演企業也表明了項目落地的意向。扶持力度大、政策體系全、創新活力足，武漢正以其特有的魅力吸引產業集聚、資本賦能，形成創投活躍的濃厚氛圍。 說到本次產業路演活動的主題，新材料作爲實體經濟的重要內容，是支撐前沿科技及新興產業發展的基石，也是增強產業鏈供應鏈自主可控能力的關鍵。 據統計，2021年我國新材料總產值有望突破7萬億元。預計2025 年新材料產業總產值實現10萬億。回望過去，我國新材料科技領域取得了長足發展，優秀成果層出不窮。國家“雙碳”目標、“卡脖子”","text":"4月8日，武漢基金產業基地「創投W+」投融資路演新材料專場順利舉行。本次活動聚焦新材料行業產學研用的深度融合，彙集6個優質項目和多位互動嘉賓線上參與交流和點評，路演項目涉及超級電容器隔膜、生物基“替塑”、AES抗菌抗病毒、高性能電化學水處理等多種新材料，集中展示了新材料領域的優質技術成果和創新應用。 活動前期，我們進行了「創投W+」投融資路演新材料專場活動線上徵集，吸引了來自深創投、鬆禾資本、九鼎投資、青域資本等近20家投資機構的投資人報名參與。會後，基地爲投資人進行了進一步對接，企業與投資人取得了直接聯繫。 活動當天，寧波柔創納米科技有限公司、貴州唯特高新能源科技有限公司、湖北譜萊光電材料有限公司、東部灣（揚州）生物新材料有限公司、浙江楓翎新材料科技有限公司、蘇州碧順環境科技有限公司在此次路演中亮相。6家企業項目各具特色，嘉賓們對項目的營銷策略、資源支持、風險與阻力、發展戰略等方面，提出了專業疑問，項目與機構代表之間形成了良好互動，多個項目獲投資機構青睞。 有項目代表表示，參加本次活動結識了很多投資人，讓他們有機會直接對話資本，探討項目成長路徑，現場思維交流和觀點的碰撞，給企業帶來了創新思考，也讓企業發展更有信心。路演中，武漢的2家本土優質企業受到投資機構的熱切關注，線上提問交流頻繁、會後對接火熱。來自浙江和江蘇的2家路演企業也表明了項目落地的意向。扶持力度大、政策體系全、創新活力足，武漢正以其特有的魅力吸引產業集聚、資本賦能，形成創投活躍的濃厚氛圍。 說到本次產業路演活動的主題，新材料作爲實體經濟的重要內容，是支撐前沿科技及新興產業發展的基石，也是增強產業鏈供應鏈自主可控能力的關鍵。 據統計，2021年我國新材料總產值有望突破7萬億元。預計2025 年新材料產業總產值實現10萬億。回望過去，我國新材料科技領域取得了長足發展，優秀成果層出不窮。國家“雙碳”目標、“卡脖子”","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/613872623","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1580,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"content":"Our efforts will be successful. As long as we persevere, there will be no failure. Come on, everyone","text":"Our efforts will be successful. As long as we persevere, there will be no failure. Come on, everyone","html":"Our efforts will be successful. As long as we persevere, there will be no failure. Come on, everyone"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006831397,"gmtCreate":1641685819938,"gmtModify":1676533638911,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006831397","repostId":"1147279991","repostType":4,"repost":{"id":"1147279991","kind":"news","weMediaInfo":{"introduction":"提供来自华尔街的观点，观察市场，提供独道的解读视角。","home_visible":1,"media_name":"老虎锐评","id":"1005414032","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641563858,"share":"https://ttm.financial/m/news/1147279991?lang=en_US&edition=fundamental","pubTime":"2022-01-07 21:57","market":"us","language":"zh","title":"Tiger Pre-Market Watch: Non-farm data can't stop the Federal Reserve from raising interest rates in March","url":"https://stock-news.laohu8.com/highlight/detail?id=1147279991","media":"老虎锐评","summary":"盘前观察美股盘前小跌，全球新冠确诊数超过3亿（美国贡献近20%，接近6,000万）。12月非农就业：新增就业不及预期，但失业率好于预期其实现在关注非农就业数据，多多少少有点鸡肋。对于市场参与者，关注宏","content":"<p><html><head></head><body><b>Pre-market observation</b></p><p>U.S. stocks fell slightly before the market, with more than 300 million confirmed COVID-19 cases worldwide (the U.S. contributed nearly 20% to nearly 60 million).</p><p><b>December Nonfarm Payrolls: New Jobs Less Than Expected, But Unemployment Rate Better Than Expected</b></p><p>In fact, paying attention to non-farm employment data now is more or less a little chicken rib. For market participants, the logic of focusing on macro data is (1) focusing on the macro economy-> (2) inferring Fed monetary policy-> (3) judging market movements. In fact, this logical chain has always been ineffective. (1) The macroeconomic quality is the basis of the Federal Reserve's monetary policy, but the relationship between the two changes; (2) The relationship between the Fed's monetary policy and market trend is even more vague. The market can rise in the rate hike cycle, and the market can also fall during the zero interest rate period. This is why there are fewer and fewer hedge funds on Wall Street that take \"macro strategy\" as their investment strategy, while the only remaining \"macro strategy\" hedge funds have embarrassing returns.</p><p>The original (2) -> (3) relationship was very vague, but now the (1) -> (2) relationship is even more lacking. Regardless of the non-farm payroll data, the pace of the Fed's rate hike tightening liquidity will never change. That's why I say that paying attention to non-farm payroll data now is a little chicken for market participants.</p><p>December non-farm payrolls data, new jobs +199,000 (expected +450,000), unemployment +3.9% (expected +4.1%).</p><p>Like the last analysis of non-farm payroll data, in fact, the real highlights are the other two. First, how is Leisure and Hospitality, the slowest-growing occupation among the unemployed, recovering? The second point is whether the continuously sluggish labor participation rate has increased.</p><p>\"Leisure and Hospitality\" was still growing in December, but at the same pace as in November, it slowed down. The December data contains the impact of the pandemic. Generally speaking, after nearly two years of COVID-19 torment, some restaurant/hotel/entertainment industries in the United States have chosen to close their doors permanently, which is almost irreversible. To take an example known to Chinese New Yorkers, Jinfeng Restaurant (with 800 seats), a morning tea shop that has existed in Chinatown for 28 years, chose to close its doors permanently in this round of COVID-19.</p><p>The labor participation rate remained the same as last month, at 61.9%. The delay in the recovery of labor participation rate indicates that labor costs are still expensive, which means that the CPI in December will not fall soon. However, I still insist that the CPI in the first quarter of this year will drop rapidly, just like the epidemic data.</p><p>In summary, although the unemployment rate was better than expected, nothing else was satisfactory. However, whether the data is good or not, it can't stop the Fed from raising interest rates in March.</p><p><img src=\"https://static.tigerbbs.com/3202d6698fcff5cf78ea08a7ff55f2da\" tg-width=\"936\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/></p><p><b>Company News</b></p><p>Moderna (MRNA): CEO Bancel warns that the efficacy of booster shots may decline over time. People may need to get a fourth shot this fall for enhanced protection. Currently, the CDC recommends a booster shot six months after two doses of the Moderna COVID vaccine.</p><p>Quidel (QDEL): Expected Q4 revenue of $633 million to $637 million, ahead of market estimates of $466 million. The increase in revenue expectations is mainly benefited from increased demand for COVID testing and other disease testing.</p><p><a href=\"https://laohu8.com/S/TSLA\">Tesla</a>(TSLA): US Model X Plaid starts at $126,490 from $119,990. The reason is the removal of other seating configuration options for this model, all stipulated as a 6-seater configuration priced at $6,500, with deliveries expected to begin in October.</p><p>Tesla (TSLA): 15 Semi electric semi-trailers may be delivered to PepsiCo (PEP) this month. PepsiCo announced last March that it would take delivery of the Tesla Semi electric semi-trailer, and Tesla began producing the vehicle at the Nevada Gigafactory last December.</p><p><a href=\"https://laohu8.com/S/AAPL\">Apple</a>(AAPL): CEO Cook's total 2021 compensation was $98.7 million. Base salary of $3 million and stock compensation of $82.34 million will be awarded in time instalments, including time-based stock of $37.5 million and performance-based stock of $44.8 million.</p><p>SONO: International Trade Commission rules<a href=\"https://laohu8.com/S/GOOG\">Google</a>(GOOGL) infringed some audio patents on its Nest speakers. Google said it plans to appeal the ruling.</p><p>T-Mobile (TMUS): net gain of 844,000 paid subscribers in Q4, missing market expectations of 868,000. The total number of new subscribers added in 2021 was approximately 2.9 million.</p><p><a href=\"https://laohu8.com/S/NYT\">The New York Times</a>(NYT): Announced The $550 million acquisition of sports news site The Athletic. The Athletic has more than 1 million subscribers, and The deal is expected to close in The first quarter, and The site will remain a standalone project in The future. The New York Times currently has more than 8 million subscribers.</p><p><a href=\"https://laohu8.com/S/CZR\">Caesars Entertainment</a>(CZR) & DraftKings (DKNG): The New York State Gaming Commission has announced that four companies can start sports betting on the mobile side in New York. Caesars, DraftKings, FanDuel, and Rush Street Interactive can start operating mobile sports betting on Saturday mornings.</p><p><b>other</b></p><p>Worldwide, 300,451,850 (+1,966,759) cases were diagnosed and 5,474,348 (+6,143) deaths were performed.</p><p>There were 58,487,940 (+610,989) confirmed cases and 833,989 (+1,404) deaths in the United States.</p><p>New York State confirmed 3,890,666 (+84,202) cases and 60,166 (+130) deaths.</p><p>Non-farm payrolls in the United States increased by 199,000 in December, compared with the expected 447,000, and the previous value of 210,000.</p><p>The CDC director will hold a press conference at 11 o'clock, after six Biden public health advisers during the presidential transition published articles calling on the Biden administration to adopt a new protest strategy to adapt to coexistence with the virus rather than completely eliminate it.</p><p>Federal Reserve Vice Chair Clarida's stock trading practices in the early days of the Covid pandemic have sparked new controversy.</p><p><img src=\"https://static.tigerbbs.com/568899c19bad5bedd5f1532327af0500\" tg-width=\"937\" tg-height=\"89\" referrerpolicy=\"no-referrer\"/></p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tiger Pre-Market Watch: Non-farm data can't stop the Federal Reserve from raising interest rates in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTiger Pre-Market Watch: Non-farm data can't stop the Federal Reserve from raising interest rates in March\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1005414032\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎锐评 </p>\n<p class=\"h-time smaller\">2022-01-07 21:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><b>Pre-market observation</b></p><p>U.S. stocks fell slightly before the market, with more than 300 million confirmed COVID-19 cases worldwide (the U.S. contributed nearly 20% to nearly 60 million).</p><p><b>December Nonfarm Payrolls: New Jobs Less Than Expected, But Unemployment Rate Better Than Expected</b></p><p>In fact, paying attention to non-farm employment data now is more or less a little chicken rib. For market participants, the logic of focusing on macro data is (1) focusing on the macro economy-> (2) inferring Fed monetary policy-> (3) judging market movements. In fact, this logical chain has always been ineffective. (1) The macroeconomic quality is the basis of the Federal Reserve's monetary policy, but the relationship between the two changes; (2) The relationship between the Fed's monetary policy and market trend is even more vague. The market can rise in the rate hike cycle, and the market can also fall during the zero interest rate period. This is why there are fewer and fewer hedge funds on Wall Street that take \"macro strategy\" as their investment strategy, while the only remaining \"macro strategy\" hedge funds have embarrassing returns.</p><p>The original (2) -> (3) relationship was very vague, but now the (1) -> (2) relationship is even more lacking. Regardless of the non-farm payroll data, the pace of the Fed's rate hike tightening liquidity will never change. That's why I say that paying attention to non-farm payroll data now is a little chicken for market participants.</p><p>December non-farm payrolls data, new jobs +199,000 (expected +450,000), unemployment +3.9% (expected +4.1%).</p><p>Like the last analysis of non-farm payroll data, in fact, the real highlights are the other two. First, how is Leisure and Hospitality, the slowest-growing occupation among the unemployed, recovering? The second point is whether the continuously sluggish labor participation rate has increased.</p><p>\"Leisure and Hospitality\" was still growing in December, but at the same pace as in November, it slowed down. The December data contains the impact of the pandemic. Generally speaking, after nearly two years of COVID-19 torment, some restaurant/hotel/entertainment industries in the United States have chosen to close their doors permanently, which is almost irreversible. To take an example known to Chinese New Yorkers, Jinfeng Restaurant (with 800 seats), a morning tea shop that has existed in Chinatown for 28 years, chose to close its doors permanently in this round of COVID-19.</p><p>The labor participation rate remained the same as last month, at 61.9%. The delay in the recovery of labor participation rate indicates that labor costs are still expensive, which means that the CPI in December will not fall soon. However, I still insist that the CPI in the first quarter of this year will drop rapidly, just like the epidemic data.</p><p>In summary, although the unemployment rate was better than expected, nothing else was satisfactory. However, whether the data is good or not, it can't stop the Fed from raising interest rates in March.</p><p><img src=\"https://static.tigerbbs.com/3202d6698fcff5cf78ea08a7ff55f2da\" tg-width=\"936\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/></p><p><b>Company News</b></p><p>Moderna (MRNA): CEO Bancel warns that the efficacy of booster shots may decline over time. People may need to get a fourth shot this fall for enhanced protection. Currently, the CDC recommends a booster shot six months after two doses of the Moderna COVID vaccine.</p><p>Quidel (QDEL): Expected Q4 revenue of $633 million to $637 million, ahead of market estimates of $466 million. The increase in revenue expectations is mainly benefited from increased demand for COVID testing and other disease testing.</p><p><a href=\"https://laohu8.com/S/TSLA\">Tesla</a>(TSLA): US Model X Plaid starts at $126,490 from $119,990. The reason is the removal of other seating configuration options for this model, all stipulated as a 6-seater configuration priced at $6,500, with deliveries expected to begin in October.</p><p>Tesla (TSLA): 15 Semi electric semi-trailers may be delivered to PepsiCo (PEP) this month. PepsiCo announced last March that it would take delivery of the Tesla Semi electric semi-trailer, and Tesla began producing the vehicle at the Nevada Gigafactory last December.</p><p><a href=\"https://laohu8.com/S/AAPL\">Apple</a>(AAPL): CEO Cook's total 2021 compensation was $98.7 million. Base salary of $3 million and stock compensation of $82.34 million will be awarded in time instalments, including time-based stock of $37.5 million and performance-based stock of $44.8 million.</p><p>SONO: International Trade Commission rules<a href=\"https://laohu8.com/S/GOOG\">Google</a>(GOOGL) infringed some audio patents on its Nest speakers. Google said it plans to appeal the ruling.</p><p>T-Mobile (TMUS): net gain of 844,000 paid subscribers in Q4, missing market expectations of 868,000. The total number of new subscribers added in 2021 was approximately 2.9 million.</p><p><a href=\"https://laohu8.com/S/NYT\">The New York Times</a>(NYT): Announced The $550 million acquisition of sports news site The Athletic. The Athletic has more than 1 million subscribers, and The deal is expected to close in The first quarter, and The site will remain a standalone project in The future. The New York Times currently has more than 8 million subscribers.</p><p><a href=\"https://laohu8.com/S/CZR\">Caesars Entertainment</a>(CZR) & DraftKings (DKNG): The New York State Gaming Commission has announced that four companies can start sports betting on the mobile side in New York. Caesars, DraftKings, FanDuel, and Rush Street Interactive can start operating mobile sports betting on Saturday mornings.</p><p><b>other</b></p><p>Worldwide, 300,451,850 (+1,966,759) cases were diagnosed and 5,474,348 (+6,143) deaths were performed.</p><p>There were 58,487,940 (+610,989) confirmed cases and 833,989 (+1,404) deaths in the United States.</p><p>New York State confirmed 3,890,666 (+84,202) cases and 60,166 (+130) deaths.</p><p>Non-farm payrolls in the United States increased by 199,000 in December, compared with the expected 447,000, and the previous value of 210,000.</p><p>The CDC director will hold a press conference at 11 o'clock, after six Biden public health advisers during the presidential transition published articles calling on the Biden administration to adopt a new protest strategy to adapt to coexistence with the virus rather than completely eliminate it.</p><p>Federal Reserve Vice Chair Clarida's stock trading practices in the early days of the Covid pandemic have sparked new controversy.</p><p><img src=\"https://static.tigerbbs.com/568899c19bad5bedd5f1532327af0500\" tg-width=\"937\" tg-height=\"89\" referrerpolicy=\"no-referrer\"/></p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1c7221d934f1008e531bdf79c8cfe0ee","relate_stocks":{"518880":"黄金ETF华安","QID":"两倍做空纳斯达克指数ETF-ProShares",".IXIC":"NASDAQ Composite","SQQQ":"纳指三倍做空ETF","DJX":"1/100道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index","BK4534":"瑞士信贷持仓","QQQ":"纳指100ETF","DDM":"2倍做多道指ETF-ProShares","TQQQ":"纳指三倍做多ETF",".DJI":"道琼斯","QLD":"2倍做多纳斯达克100指数ETF-ProShares","PSQ":"做空纳斯达克100指数ETF-ProShares"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147279991","content_text":"盘前观察美股盘前小跌，全球新冠确诊数超过3亿（美国贡献近20%，接近6,000万）。12月非农就业：新增就业不及预期，但失业率好于预期其实现在关注非农就业数据，多多少少有点鸡肋。对于市场参与者，关注宏观数据的逻辑是（1）关注宏观经济->（2）推断美联储货币政策->（3）判断市场走势。其实这个逻辑链条一直以来都不太有效，（1）宏观经济好坏是美联储货币政策的依据，但两者的关系变来变去；（2）美联储货币政策和市场走势的关系就更模糊了，加息周期市场可以涨，0利率期间市场也可以跌。这也就是为何当下华尔街以“宏观策略”作为投资策略的对冲基金越来越少，而仅存的“宏观策略”对冲基金收益都比较尴尬。原来（2）->（3）的关系就很模糊，现在（1）->（2）的关系就更缺乏了。不管非农就业数据怎么样，美联储加息收紧流动性的步伐绝对不会改变。这就是我为何说现在关注非农就业数据，对于市场参与者有点鸡肋的原因。12月非农就业数据，新增就业+199,000（预期+450,000），失业率+3.9%（预期+4.1%）。和上次非农就业数据分析一样，其实真正的看点是另外两个。第一个看点，失业人口中增长最缓慢的职业“Leisure and Hospitality”（酒店餐馆服务业）恢复得怎么样？第二个看点，就是持续低迷的劳动参与率有没有提高。“Leisure and Hospitality”12月仍在增长，但增速和11月一样，慢下来了。12月的数据包含了疫情的影响。总的来说，经过近两年新冠的折磨，美国有的餐馆/酒店/娱乐行业已经选择了永久关门，这一点几乎不可逆。举一个纽约华人知道的例子，在唐人街存在了28年的早茶店金丰大酒楼（拥有800个座位），在这一轮新冠中选择了永久关门。劳动参与率和上个月一样，依旧是61.9%。劳动参与率迟迟不能恢复，就预示了劳动力成本依然贵，也就说明12月的CPI不会很快回落。不过我还是坚持认为，今年1季度的CPI，会迅速回落，和疫情数据一样。总结一下，尽管失业率比预期的好，但其它数据都不尽如人意。不过数据好或者不好，都不能阻挡美联储3月加息。公司新闻Moderna(MRNA)：CEO Bancel警告称，加强针的功效可能会随着时间推移而下降。人们可能需要在今年秋季注射第四针以增强保护。目前CDC建议注射两剂Moderna新冠疫苗6个月后注射加强针。Quidel(QDEL)：预计4季度营收$6.33亿至$6.37亿，高于市场预期$4.66亿。营收预期上涨主要受益于新冠检测和其他疾病检测的需求增加。特斯拉(TSLA)：美国Model X Plaid起价从$119,990升至$126,490。原因是取消了该车型的其他座椅配置选择，均规定为价格$6,500的6座配置，预计10月开始交付。特斯拉(TSLA)：本月或将向百事(PEP)交付15辆Semi电动半挂车。百事去年3月宣布将接收特斯拉Semi电动半挂车，特斯拉去年12月开始在内华达超级工厂生产这款车。苹果(AAPL)：CEO库克2021年总薪酬$9,870万。基本工资$300万，股票报酬$8,234万，将按时间分期授予，包括基于时间的股票$3,750万和基于绩效的股票$4,480万。索诺声(SONO)：国际贸易委员会裁定谷歌(GOOGL)侵犯了其Nest扬声器的部分音频专利。谷歌表示计划对该裁决提起上诉。T-Mobile(TMUS)：4季度付费用户净增844,000个，低于市场预期868,000个。2021年新增用户总数约为290万。纽约时报(NYT)：宣布以$5.5亿收购体育新闻网站The Athletic。The Athletic拥有超过100万订阅用户，预计交易会在1季度完成，后续该网站将仍是独立项目。目前纽约时报拥有超过800万订阅用户。凯撒娱乐(CZR) & DraftKings(DKNG)：纽约州博彩委员会宣布4家公司可在纽约开展移动端的体育博彩业务。凯撒、DraftKings、FanDuel和Rush Street Interactive可在周六上午开始运营移动端体育博彩。其它全球确诊300,451,850(+1,966,759)例，死亡5,474,348(+6,143)例。美国确诊58,487,940(+610,989)例，死亡833,989(+1,404)例。纽约州确诊3,890,666(+84,202)例，死亡60,166(+130)例。美国12月非农就业人口增加19.9万，预期44.7万，前值21万。美CDC主管将于11点召开新闻发布会，此前拜登6位在总统交接时期公共卫生顾问发表文章，呼吁拜登政府采取新的抗议策略，适应与病毒共存而非彻底消除病毒。美联储副主席Clarida在新冠疫情爆发初期的股票交易行为引发新的争议。","news_type":1,"symbols_score_info":{"518880":0.9,"SPY":0.9,"NQmain":0.9,"TQQQ":0.9,"SImain":0.9,"QQQ":0.9,"PSQ":0.9,"DDM":0.9,".DJI":0.9,"GCmain":0.9,"SGCmain":0.9,"SQQQ":0.9,"QLD":0.9,"QID":0.9,".IXIC":0.9,"DJX":0.9,"MNQmain":0.9,"SGUmain":0.9,".SPX":0.9,"MGCmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9014423797,"gmtCreate":1649712832480,"gmtModify":1676534553309,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014423797","repostId":"2226688741","repostType":4,"isVote":1,"tweetType":1,"viewCount":2012,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096782019,"gmtCreate":1644461751143,"gmtModify":1676533929902,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096782019","repostId":"1120878270","repostType":4,"repost":{"id":"1120878270","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644459301,"share":"https://ttm.financial/m/news/1120878270?lang=en_US&edition=fundamental","pubTime":"2022-02-10 10:15","market":"hk","language":"zh","title":"Lepu Biotech starts its IPO today, with an admission fee of HK$7454.38","url":"https://stock-news.laohu8.com/highlight/detail?id=1120878270","media":"老虎资讯综合","summary":"每股发售价介于6.87港元-7.38港元，每手1000股。","content":"<p><html><head></head><body>February 10th news,<a href=\"https://laohu8.com/S/02157\">Lepu Bio-B</a>Announcement: From February 10 to February 15, 2022, the Company intends to issue approximately 127 million shares, of which the Hong Kong Public Offering accounts for 10%, the International Offering accounts for 90%, and the over-allotment option of 15% is attached.<b>Offer price of HK$6.87-HK$7.38 per share, board lot of 1000 shares, admission fee of HK$7454.38</b>Dealings in the Shares on the Stock Exchange are expected to commence on 23 February 2022.</p><p><img src=\"https://static.tigerbbs.com/97e1a27c96f3078f3c0b6f92bab54cb8\" tg-width=\"869\" tg-height=\"610\" referrerpolicy=\"no-referrer\"/></p><p><b>Purchase ladder</b></p><p>Each lot of 1000 shares, the entrance fee is HK$7454.38.</p><p>The threshold of Group B is 70,000 shares, and the funds required for subscription are about HK$ 521,806.55.<img src=\"https://static.tigerbbs.com/64702a21d77baa3223cdcc943a37271a\" tg-width=\"800\" tg-height=\"600\" referrerpolicy=\"no-referrer\"/></p><p><b>Company Profile</b></p><p>Founded in 2018, Lepu Bio has completed three rounds of financing in the past four years, attracting many professional investment funds in the pharmaceutical and medical industry, including Vivo Capital, Suzhou Danqing, SDIC Chuanghe, Ping An Capital, Sunshine Life Insurance, Ronghui Sunshine, Guoxin Central Enterprise, Shanghai Biomedical Fund, etc.</p><p><b>Differentiated layout of PD-1 pan-cancer immunotherapy</b></p><p>Lepu Bio focuses on the combination drug mechanism in the field of tumor therapy, which is<b>The only innovative drug company in China with both PD-1 monoclonal antibodies in the NDA reporting stage and multiple clinical phase II ADC pipelines.</b>There are 8 clinical-stage drug candidates in its product pipeline, mainly composed of targeted therapies (ADC antibody conjugate drugs) and immunotherapy drugs, the latter including two immune checkpoint drugs (PD-1/L1) and one oncolytic virus drug. Three drug candidates have entered registration trials, and two trials are ongoing in the United States. Monoclonal antibody cornerstone products can form combination drug advantages with ADCs, oncolytic viruses, etc. The company will also expand the beneficiary patient population and improve the quality of life of patients.</p><p><img src=\"https://static.tigerbbs.com/893211e958a9d22abefebb7472519142\" tg-width=\"1080\" tg-height=\"606\" referrerpolicy=\"no-referrer\"/></p><p>Source: Prospectus</p><p>The domestic competition for PD-1 (L1) has been extremely fierce, so many companies have begun to target the more cutting-edge therapeutic market. The second indication of PD-1 Putelizumab Injection (HX008), one of the core products of Lepu Bio. The marketing application for MSI-H/dMMR solid tumors was included in the priority review by CDE in November 2021.</p><p>MSI-H/dMMR is the first \"pan-tumor\" tumor marker, and the discovery of MSI-H/dMMR tumor marker has promoted the progress of the tumor treatment approach of \"treating by type regardless of cancer type\". As an emerging immunotherapy biomarker, MSI-H/dMMR has a high detection rate in digestive system cancers such as gastric cancer and colorectal cancer, so it has a wide application prospect. But the competition in the MSI-H/dMMR solid tumor treatment market has just begun. Currently, the global<b>Only three anti-PD- (L) 1 monoclonal antibodies (approved by NMPA), K drug (pembrolizumab, approved by FDA and NMPA), O drug (nivolumab, approved by FDA) and envolizumab, have been approved for the treatment of MSI-H/dMMR solid tumors.</b></p><p>Taking K drug as an example, in a global multicenter large-scale phase III clinical trial of pembrolizumab for the first-line treatment of intestinal cancer, the 3-year survival rate, PFS, ORR, CRR, TRAE and other performances of patients with advanced intestinal cancer using K drug were significantly better than those of patients with advanced intestinal cancer using conventional chemotherapy. The NDA application for HX008 submitted by Lepu Bio has been accepted. HX008 is expected to become the first market product of Lepu Bio and enable patients to benefit from new therapies earlier.</p><p><b>It is also worth mentioning that PD-1 is closest to commercialization in the overall strategic deployment of Lepu Bio and plays an important role. The company will use PD-1 products to open up sales channels, and plans to start marketing in medical institutions and pharmacies after HX008 is approved for the treatment of MSI-H/dMMR solid tumors and melanoma in China, so as to lay the foundation for the smooth listing of ADC products and subsequent pipelines</b>。</p><p><b>Several ADCs are expected to achieve world first</b></p><p>ADC drugs are the core of Lepu Biological's targeted therapy. The company has a variety of targeted ADC drug pipelines, among which the core pipeline HER2 targeted ADC drug MRG002 has the fastest commercialization progress. Lepu Bio has a relatively complete layout in the field of breast cancer treatment, especially one of its core products, MRG002, is a HER2-targeted ADC drug. The HER2 positivity rate in breast cancer is about 25.4%. The second-line progression rate of breast cancer in China is 94.3%.</p><p>Breast cancer is now the most common type of cancer in the world, and the number of new breast cancer cases in China reached 331,600 in 2020. According to Frost & Sullivan, the size of the breast cancer market in China was RMB50.7 billion in 2020 and is expected to reach RMB81.8 billion and RMB124.6 billion by 2025 and 2030, respectively.</p><p>MRG002 has achieved a breakthrough in phase II clinical studies. This Phase II clinical trial was led by Professor Jiang Zefei of the People's Liberation Army General Hospital, who gave a detailed report in the special session on innovative drug clinical research data at the CSCO Annual Meeting in September 2021. Jiang Zefei said that the innovative efficacy of MRG002 comes from its innovative molecular design, because ADC drug design has unique difficulties in cytotoxicity and linkers.</p><p>There has never been a shortage of blockbuster varieties in the global breast cancer treatment market. According to Nature Reviews Drug Discovery, the global sales of ADCs currently on the market will exceed $16.4 billion in 2026.</p><p>Another core pipeline, MRG003, is an EGFR-targeted ADC drug candidate. According to Frost & Sullivan, MRG003 is currently<b>Domestic first and international clinical progress leading</b>For ADC drugs targeting EGFR, worldwide, except Japan's Rakuten Medical's product Akalux (suitable for irresectable locally recurrent head and neck cancer), which has been approved by PMDA, no other ADC targeting EGFR has been approved. Lepu Bio is conducting a number of phase II clinical trials for MRG003 in China.</p><p>Similarly, other ADC pipelines also have the potential to be first of its kind. For example, CMG901 jointly developed by Lepu Bio and Connoya (2162.HK) is the world's first CLDN18.2-targeted ADC approved by IND; The company's self-developed MRG001 is aimed at hematological tumors. There is currently no approved CD20-targeted ADC product in the world. The only CD20-targeted ADCs in the clinical stage in China are the company's MRG001 and Territh's TRS005.</p><p><b>ADC drug technology is complex, and many pipelines will face the challenge of early R&D failure; In addition, for ADC drugs to be finally approved for marketing, the company's ADC commercial production capacity and production experience are also crucial.</b>Dr. Hu Chaohong, co-general manager of Lepu Bio, has worked at Seagen (SGEN.US) for many years, and the team has rich experience in ADC drug development. Lepu Bio also has a clinically proven ADC platform for coupling and CMC technologies, as well as a development and analysis platform for advanced processes as support for commercial production.</p><p><b>Clinical progress of oncolytic virus leads the world</b></p><p>Lepu Bio introduced the innovative pipeline CG0070 from CG Oncology and obtained the right to develop, manufacture and commercialize the product in China. The company has submitted an IND application to the State Food and Drug Administration for intravesical administration of CG0070 for the treatment of bladder cancer (NMIBC, non-muscle invasive bladder cancer that does not respond to BCG) and other solid tumors.<b>The application for NMIBC has been clinically approved by CDE,</b>Conduct clinical trials for this indication.</p><p>According to Frost & Sullivan,<b>CG0070 is the first and only oncolytic adenovirus in clinical development for bladder cancer</b>。 Oncolytic viruses are a class of viruses that can selectively lyse cancer cells. On the one hand, they can infect tumor cells and cause cell lysis; On the other hand, the molecules they release during lysis can also induce innate and adaptive immune responses, attracting more immune cells to continue to kill residual tumor cells, so oncolytic viruses have good clinical prospects as innovative therapies.</p><p>The main indication of oncolytic virus is bladder cancer, which is the most common malignant tumor of the urinary system and has the highest incidence of urogenital tract tumors in China.<b>With a five-year survival rate of 72.9% in China, there are significant market opportunities for bladder cancer treatment.</b>In addition, the oncolytic virus can also be expanded to other indications, especially in combination,<b>The combination of oncolytic virus and anti-PD-1/anti-PD-L1 monoclonal antibodies has emerged as an emerging treatment for advanced malignancies.</b></p><p>CG0070 has shown good safety and efficacy in the Phase II clinical study conducted by CG Oncology in the United States for the treatment of NMIBC. On November 13, 2021, CG Oncology disclosed the very eye-catching Phase II clinical trial data of CG0070 combined with K drug.<b>The trial results showed that among the 9 NMIBC patients with evaluable efficacy, all patients achieved complete response (CR) at 3 months. In addition, the CR rate of patients who reached the 6-month evaluation node and the 9-month evaluation node was also maintained 100%.</b></p><p>Many companies around the world have laid out a total of more than 180 oncolytic virus pipelines, but at present, CG Oncology and Candel Therapeutics (CADL.US)' aglatimagene besadenovec (which has entered clinical phase III for the treatment of prostate cancer) are among the faster-progressing pipelines.</p><p>In addition to CG0070, Lepu Bio also has a stake in Wuhan Binhui Bio, which independently developed recombinant human GM-CSF oncolytic type II herpes simplex virus (OH2) injection. The prospectus of Lepu Bio shows that the combination therapy of HX008 combined with OH2 for advanced hepatocellular carcinoma has been approved for IND and the corresponding phase I clinical trial has started.</p><p>Lepu Bio has established multiple tumor treatment pipelines for multiple indications. As product commercialization approaches, the company is also promoting research on the combination of monoclonal antibodies with other core pipelines, with a view to providing patients with innovative and even disruptive treatment options. In addition to the above HX008 combined with OH2, Lepu Bio also plans to develop ADC combined with HX008 for the treatment of advanced head and neck squamous cell carcinoma (HNSCC). MRG003 in combination with HX008 for HNSCC and MRG002 in combination with HX008 for gastric cancer have received IND approval from the NMPA.</p><p>From a global perspective, in clinical trials of monoclonal antibody products such as K drugs combined with ADCs and oncolytic viruses, combination therapy generally shows a higher complete remission rate than single drugs, and the survival rate of patients participating in combination chemotherapy trials is also improving.</p><p>While advancing the development of product candidates, the company has planned and is implementing the production and commercialization layout. In 2019, Lepu Bio built and put into production a GMP-standard 2,000L antibody production line in Beijing, and is currently building a 200L oncolytic virus drug production line in Beijing. At present, the company is also building a biomedical production center in Shanghai, including the construction of a production line with a preliminary designed capacity of 12,000L and supporting laboratories and factories. Relying on the company's team and technology platform, the construction of production and commercialization capabilities will also provide great support for the company's global layout.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lepu Biotech starts its IPO today, with an admission fee of HK$7454.38</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLepu Biotech starts its IPO today, with an admission fee of HK$7454.38\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2022-02-10 10:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>February 10th news,<a href=\"https://laohu8.com/S/02157\">Lepu Bio-B</a>Announcement: From February 10 to February 15, 2022, the Company intends to issue approximately 127 million shares, of which the Hong Kong Public Offering accounts for 10%, the International Offering accounts for 90%, and the over-allotment option of 15% is attached.<b>Offer price of HK$6.87-HK$7.38 per share, board lot of 1000 shares, admission fee of HK$7454.38</b>Dealings in the Shares on the Stock Exchange are expected to commence on 23 February 2022.</p><p><img src=\"https://static.tigerbbs.com/97e1a27c96f3078f3c0b6f92bab54cb8\" tg-width=\"869\" tg-height=\"610\" referrerpolicy=\"no-referrer\"/></p><p><b>Purchase ladder</b></p><p>Each lot of 1000 shares, the entrance fee is HK$7454.38.</p><p>The threshold of Group B is 70,000 shares, and the funds required for subscription are about HK$ 521,806.55.<img src=\"https://static.tigerbbs.com/64702a21d77baa3223cdcc943a37271a\" tg-width=\"800\" tg-height=\"600\" referrerpolicy=\"no-referrer\"/></p><p><b>Company Profile</b></p><p>Founded in 2018, Lepu Bio has completed three rounds of financing in the past four years, attracting many professional investment funds in the pharmaceutical and medical industry, including Vivo Capital, Suzhou Danqing, SDIC Chuanghe, Ping An Capital, Sunshine Life Insurance, Ronghui Sunshine, Guoxin Central Enterprise, Shanghai Biomedical Fund, etc.</p><p><b>Differentiated layout of PD-1 pan-cancer immunotherapy</b></p><p>Lepu Bio focuses on the combination drug mechanism in the field of tumor therapy, which is<b>The only innovative drug company in China with both PD-1 monoclonal antibodies in the NDA reporting stage and multiple clinical phase II ADC pipelines.</b>There are 8 clinical-stage drug candidates in its product pipeline, mainly composed of targeted therapies (ADC antibody conjugate drugs) and immunotherapy drugs, the latter including two immune checkpoint drugs (PD-1/L1) and one oncolytic virus drug. Three drug candidates have entered registration trials, and two trials are ongoing in the United States. Monoclonal antibody cornerstone products can form combination drug advantages with ADCs, oncolytic viruses, etc. The company will also expand the beneficiary patient population and improve the quality of life of patients.</p><p><img src=\"https://static.tigerbbs.com/893211e958a9d22abefebb7472519142\" tg-width=\"1080\" tg-height=\"606\" referrerpolicy=\"no-referrer\"/></p><p>Source: Prospectus</p><p>The domestic competition for PD-1 (L1) has been extremely fierce, so many companies have begun to target the more cutting-edge therapeutic market. The second indication of PD-1 Putelizumab Injection (HX008), one of the core products of Lepu Bio. The marketing application for MSI-H/dMMR solid tumors was included in the priority review by CDE in November 2021.</p><p>MSI-H/dMMR is the first \"pan-tumor\" tumor marker, and the discovery of MSI-H/dMMR tumor marker has promoted the progress of the tumor treatment approach of \"treating by type regardless of cancer type\". As an emerging immunotherapy biomarker, MSI-H/dMMR has a high detection rate in digestive system cancers such as gastric cancer and colorectal cancer, so it has a wide application prospect. But the competition in the MSI-H/dMMR solid tumor treatment market has just begun. Currently, the global<b>Only three anti-PD- (L) 1 monoclonal antibodies (approved by NMPA), K drug (pembrolizumab, approved by FDA and NMPA), O drug (nivolumab, approved by FDA) and envolizumab, have been approved for the treatment of MSI-H/dMMR solid tumors.</b></p><p>Taking K drug as an example, in a global multicenter large-scale phase III clinical trial of pembrolizumab for the first-line treatment of intestinal cancer, the 3-year survival rate, PFS, ORR, CRR, TRAE and other performances of patients with advanced intestinal cancer using K drug were significantly better than those of patients with advanced intestinal cancer using conventional chemotherapy. The NDA application for HX008 submitted by Lepu Bio has been accepted. HX008 is expected to become the first market product of Lepu Bio and enable patients to benefit from new therapies earlier.</p><p><b>It is also worth mentioning that PD-1 is closest to commercialization in the overall strategic deployment of Lepu Bio and plays an important role. The company will use PD-1 products to open up sales channels, and plans to start marketing in medical institutions and pharmacies after HX008 is approved for the treatment of MSI-H/dMMR solid tumors and melanoma in China, so as to lay the foundation for the smooth listing of ADC products and subsequent pipelines</b>。</p><p><b>Several ADCs are expected to achieve world first</b></p><p>ADC drugs are the core of Lepu Biological's targeted therapy. The company has a variety of targeted ADC drug pipelines, among which the core pipeline HER2 targeted ADC drug MRG002 has the fastest commercialization progress. Lepu Bio has a relatively complete layout in the field of breast cancer treatment, especially one of its core products, MRG002, is a HER2-targeted ADC drug. The HER2 positivity rate in breast cancer is about 25.4%. The second-line progression rate of breast cancer in China is 94.3%.</p><p>Breast cancer is now the most common type of cancer in the world, and the number of new breast cancer cases in China reached 331,600 in 2020. According to Frost & Sullivan, the size of the breast cancer market in China was RMB50.7 billion in 2020 and is expected to reach RMB81.8 billion and RMB124.6 billion by 2025 and 2030, respectively.</p><p>MRG002 has achieved a breakthrough in phase II clinical studies. This Phase II clinical trial was led by Professor Jiang Zefei of the People's Liberation Army General Hospital, who gave a detailed report in the special session on innovative drug clinical research data at the CSCO Annual Meeting in September 2021. Jiang Zefei said that the innovative efficacy of MRG002 comes from its innovative molecular design, because ADC drug design has unique difficulties in cytotoxicity and linkers.</p><p>There has never been a shortage of blockbuster varieties in the global breast cancer treatment market. According to Nature Reviews Drug Discovery, the global sales of ADCs currently on the market will exceed $16.4 billion in 2026.</p><p>Another core pipeline, MRG003, is an EGFR-targeted ADC drug candidate. According to Frost & Sullivan, MRG003 is currently<b>Domestic first and international clinical progress leading</b>For ADC drugs targeting EGFR, worldwide, except Japan's Rakuten Medical's product Akalux (suitable for irresectable locally recurrent head and neck cancer), which has been approved by PMDA, no other ADC targeting EGFR has been approved. Lepu Bio is conducting a number of phase II clinical trials for MRG003 in China.</p><p>Similarly, other ADC pipelines also have the potential to be first of its kind. For example, CMG901 jointly developed by Lepu Bio and Connoya (2162.HK) is the world's first CLDN18.2-targeted ADC approved by IND; The company's self-developed MRG001 is aimed at hematological tumors. There is currently no approved CD20-targeted ADC product in the world. The only CD20-targeted ADCs in the clinical stage in China are the company's MRG001 and Territh's TRS005.</p><p><b>ADC drug technology is complex, and many pipelines will face the challenge of early R&D failure; In addition, for ADC drugs to be finally approved for marketing, the company's ADC commercial production capacity and production experience are also crucial.</b>Dr. Hu Chaohong, co-general manager of Lepu Bio, has worked at Seagen (SGEN.US) for many years, and the team has rich experience in ADC drug development. Lepu Bio also has a clinically proven ADC platform for coupling and CMC technologies, as well as a development and analysis platform for advanced processes as support for commercial production.</p><p><b>Clinical progress of oncolytic virus leads the world</b></p><p>Lepu Bio introduced the innovative pipeline CG0070 from CG Oncology and obtained the right to develop, manufacture and commercialize the product in China. The company has submitted an IND application to the State Food and Drug Administration for intravesical administration of CG0070 for the treatment of bladder cancer (NMIBC, non-muscle invasive bladder cancer that does not respond to BCG) and other solid tumors.<b>The application for NMIBC has been clinically approved by CDE,</b>Conduct clinical trials for this indication.</p><p>According to Frost & Sullivan,<b>CG0070 is the first and only oncolytic adenovirus in clinical development for bladder cancer</b>。 Oncolytic viruses are a class of viruses that can selectively lyse cancer cells. On the one hand, they can infect tumor cells and cause cell lysis; On the other hand, the molecules they release during lysis can also induce innate and adaptive immune responses, attracting more immune cells to continue to kill residual tumor cells, so oncolytic viruses have good clinical prospects as innovative therapies.</p><p>The main indication of oncolytic virus is bladder cancer, which is the most common malignant tumor of the urinary system and has the highest incidence of urogenital tract tumors in China.<b>With a five-year survival rate of 72.9% in China, there are significant market opportunities for bladder cancer treatment.</b>In addition, the oncolytic virus can also be expanded to other indications, especially in combination,<b>The combination of oncolytic virus and anti-PD-1/anti-PD-L1 monoclonal antibodies has emerged as an emerging treatment for advanced malignancies.</b></p><p>CG0070 has shown good safety and efficacy in the Phase II clinical study conducted by CG Oncology in the United States for the treatment of NMIBC. On November 13, 2021, CG Oncology disclosed the very eye-catching Phase II clinical trial data of CG0070 combined with K drug.<b>The trial results showed that among the 9 NMIBC patients with evaluable efficacy, all patients achieved complete response (CR) at 3 months. In addition, the CR rate of patients who reached the 6-month evaluation node and the 9-month evaluation node was also maintained 100%.</b></p><p>Many companies around the world have laid out a total of more than 180 oncolytic virus pipelines, but at present, CG Oncology and Candel Therapeutics (CADL.US)' aglatimagene besadenovec (which has entered clinical phase III for the treatment of prostate cancer) are among the faster-progressing pipelines.</p><p>In addition to CG0070, Lepu Bio also has a stake in Wuhan Binhui Bio, which independently developed recombinant human GM-CSF oncolytic type II herpes simplex virus (OH2) injection. The prospectus of Lepu Bio shows that the combination therapy of HX008 combined with OH2 for advanced hepatocellular carcinoma has been approved for IND and the corresponding phase I clinical trial has started.</p><p>Lepu Bio has established multiple tumor treatment pipelines for multiple indications. As product commercialization approaches, the company is also promoting research on the combination of monoclonal antibodies with other core pipelines, with a view to providing patients with innovative and even disruptive treatment options. In addition to the above HX008 combined with OH2, Lepu Bio also plans to develop ADC combined with HX008 for the treatment of advanced head and neck squamous cell carcinoma (HNSCC). MRG003 in combination with HX008 for HNSCC and MRG002 in combination with HX008 for gastric cancer have received IND approval from the NMPA.</p><p>From a global perspective, in clinical trials of monoclonal antibody products such as K drugs combined with ADCs and oncolytic viruses, combination therapy generally shows a higher complete remission rate than single drugs, and the survival rate of patients participating in combination chemotherapy trials is also improving.</p><p>While advancing the development of product candidates, the company has planned and is implementing the production and commercialization layout. In 2019, Lepu Bio built and put into production a GMP-standard 2,000L antibody production line in Beijing, and is currently building a 200L oncolytic virus drug production line in Beijing. At present, the company is also building a biomedical production center in Shanghai, including the construction of a production line with a preliminary designed capacity of 12,000L and supporting laboratories and factories. Relying on the company's team and technology platform, the construction of production and commercialization capabilities will also provide great support for the company's global layout.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c8d9586192423abb2922de7db5c64252","relate_stocks":{"02157":"乐普生物-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120878270","content_text":"2月10日消息，乐普生物-B公告：于2022年2月10日-2月15日进行招股，公司拟发行约1.27亿股，其中香港公开发售占10%，国际发售占90%，另附有15%的超额配股权。每股发售价为6.87港元-7.38港元，每手1000股，入场费7454.38港元，预期股份将于2022年2月23日在联交所开始买卖。申购阶梯每手1000股，入场费7454.38港元。乙组门槛为70000股，申购所需资金约521806.55港元。公司简介乐普生物成立于2018年，近4年一共完成了3轮融资，吸引了众多专业的医药医疗行业投资基金，包括维梧资本、苏州丹青、国投创合、平安资本、阳光人寿、融汇阳光、国新央企、上海生物医药基金等。差异化布局PD-1泛癌种免疫治疗乐普生物聚焦肿瘤治疗领域的联合用药机制，是国内唯一一家既有NDA报产阶段PD-1单抗，又拥有多个临床II期ADC管线的创新药企业。其产品管线中有8种临床阶段候选药物，主要由靶向疗法（ADC抗体偶联药物）和免疫治疗药物构成，后者包括两种免疫检查点药物（PD-1/L1）和一种溶瘤病毒药物。三项候选药物已进入注册性试验，两项试验正在美国进行。单抗类基石产品与ADC、溶瘤病毒等可形成联合用药优势，公司也将扩大受益患者群，提高患者的生存质量。来源：招股书PD-1（L1）在国内竞争已经异常激烈，因此不少企业都开始瞄准更前沿的治疗市场，乐普生物核心产品之一PD-1 普特利单抗注射液（HX008）第二个适应症MSI-H/dMMR 实体瘤的上市申请，2021年11月被CDE纳入优先评审。MSI-H/dMMR是第一个「泛瘤种」肿瘤标志物，MSI-H/dMMR肿瘤标志物的发现推动了「不分癌种，分型而治」的肿瘤治疗方式的进展。作为新兴的免疫治疗生物标志物，MSI-H/dMMR在胃癌、结直肠癌等消化系统癌症中的检出率较高，因此具有广泛的应用前景。但MSI-H/dMMR实体瘤治疗市场的竞争才刚开始。目前，全球仅获批了K药（帕博丽珠单抗，已于FDA、NMPA获批）、O药（纳武利尤单抗，已于FDA获批）及恩沃利单抗3款抗PD-(L)1单抗（已于NMPA获批）用于治疗MSI-H/dMMR实体瘤。以K药为例，在帕博利珠单抗针对肠癌一线治疗的全球多中心的大型III期临床试验中，使用K药的晚期肠癌患者的3年生存率、PFS、ORR、CRR、TRAE等表现都明显优于使用常规化疗的晚期肠癌患者。乐普生物提交的HX008的NDA申请已获受理，HX008有望成为乐普生物首个上市产品，并使患者较早从新疗法中获益。另外值得一提的是，PD-1在乐普生物整体战略部署中离商业化最近，具有重要地位。公司将借助PD-1产品来打通销售渠道，计划HX008国内获批用于治疗MSI-H/dMMR实体瘤及黑色素瘤后启动在医疗机构、药房体系的营销工作，为ADC产品及后续管线顺利上市奠定基础。多款ADC有望实现全球首创ADC药物是乐普生物靶向疗法的核心，公司拥有多种靶向ADC药物管线，其中核心管线HER2靶向ADC药物MRG002商业化进展最快。乐普生物在乳腺癌治疗领域有相对完善的布局，尤其是核心产品之一MRG002为HER2靶向ADC药物。乳腺癌的HER2阳性率约为25.4%。中国乳腺癌的二线进展率为94.3%。乳腺癌现成为全球最常见的癌种，中国2020年新增的乳腺癌病例数达到33.16万。据弗若斯特沙利文的资料，2020年中国乳腺癌市场的规模为人民币507亿元，预计至2025年及2030年将分别达到818亿元及1246亿元。MRG002在II期临床研究中已实现突破。此II期临床试验由解放军总医院江泽飞教授牵头，江泽飞在2021年9月的CSCO年会创新药物临床研究数据专场中作了详细汇报。江泽飞表示，MRG002的创新疗效来自于其创新的分子设计，因为ADC药物设计在细胞毒、连接子方面都有独特难点。全球的乳腺癌治疗市场从来不乏重磅品种。据Nature Reviews Drug Discovery预计，2026年，目前已上市ADC的全球销售额将超过164亿美元。另一项核心管线MRG003为一款EGFR靶向ADC候选药物。据弗若斯特沙利文，MRG003是目前国内首创和国际临床进度领先的靶向EGFR的ADC药物，全球范围内，除了日本Rakuten Medical的产品Akalux（适用于不能切除的局部复发性头颈癌）获PMDA批准外，还没有其他靶向EGFR的ADC获批。乐普生物正在就MRG003在中国进行多项II期临床试验。同样，ADC其他管线也具有同类首创的潜质。例如，乐普生物与康诺亚（2162.HK）合作开发的CMG901是全球首款获IND批准的CLDN18.2靶向ADC；公司自研的MRG001针对血液肿瘤，全球目前尚未有获批的CD20靶向ADC产品，国内进入临床阶段的CD20靶向ADC仅有公司的MRG001和特瑞思的TRS005。ADC药物技术复杂，很多管线会面临前期研发失败的挑战；此外，ADC药物能最终获批上市，企业的ADC商业化生产能力、生产经验也至关重要。乐普生物联席总经理胡朝红博士在Seagen（SGEN.US）工作多年，团队拥有丰富的ADC药物研发经验。乐普生物也具有经临床验证的偶联和CMC技术的ADC平台，以及先进工艺的开发分析平台作为商业化生产的支持。溶瘤病毒临床进展全球领先乐普生物从CG Oncology引进了创新型管线CG0070，获得了该产品在国内的开发、制造和商业化权利。公司已向国家药监局提交CG0070膀胱内给药治疗膀胱癌（NMIBC，即卡介苗（BCG）无应答的非肌层浸润性膀胱癌）及其他实体瘤的IND申请，针对NMIBC的申请已获CDE的临床批件，开展对该适应症的临床试验。据弗若斯特沙利文，CG0070是首个也是唯一一个处于临床开发阶段的治疗膀胱癌的溶瘤腺病毒。溶瘤病毒是一类能选择性裂解癌细胞的病毒，一方面，它们可以感染肿瘤细胞并引起细胞裂解；另一方面，它们在裂解过程中释放的分子还能诱导先天性和适应性免疫反应，吸引更多免疫细胞来继续杀死残余肿瘤细胞，因此溶瘤病毒作为创新疗法有很好的临床前景。溶瘤病毒的主要适应症为膀胱癌，膀胱癌是泌尿系统最常见的恶性肿瘤，在中国泌尿生殖道肿瘤的发病率最高，在中国的五年生存率为72.9%，膀胱癌治疗有重大的市场机会。此外，溶瘤病毒还可拓展至其他适应症，尤其能在联用中体现优势，溶瘤病毒及抗PD-1╱抗PD-L1单克隆抗体的联合已成为新兴的晚期恶性肿瘤治疗方法。CG0070在CG Oncology于美国进行的用于治疗NMIBC的临床II期研究中展现出良好的安全性及疗效， 2021年11月13日，CG Oncology披露了CG0070联合K药十分亮眼的Ⅱ期临床试验数据。试验结果显示，在可评估疗效的9名NMIBC患者中，所有患者在3个月时实现了完全缓解（CR），此外，达到6个月评估节点和9个月评估节点的患者CR率也保持了100%。全球很多家企业布局了共约180多款溶瘤病毒管线，但目前CG Oncology和美国Candel Therapeutics（CADL.US）的aglatimagene besadenovec（治疗前列腺癌进入了临床III期）属于其中进展较快的管线。除CG0070外，乐普生物还参股了武汉滨会生物，滨会生物自主开发了重组人GM-CSF溶瘤II型单纯疱疹病毒（OH2）注射液。乐普生物招股书显示，HX008联合OH2针对晚期肝细胞癌的联合疗法已经获批IND并开始相应的I期临床试验。乐普生物已建立起针对多种适应症的多个肿瘤治疗管线。随着产品商业化的临近，公司也在推进单抗与其他核心管线联用的研究，以期为患者提供创新甚至颠覆性的治疗方案。除上述HX008联合OH2外，乐普生物还计划就ADC联合HX008治疗晚期头颈部鳞状细胞癌（HNSCC）等进行研发。MRG003联合HX008治疗HNSCC，以及MRG002与HX008联合治疗胃癌均已从国家药监局获得了IND批准。而从全球来看，K药等单抗产品与ADC、溶瘤病毒联用的临床试验中，联合疗法普遍显示出较单药更高的完全缓解率，参与联合化疗试验的患者生存率也在提高。在推进候选产品开发的同时，公司已规划并正在落实生产和商业化布局。2019年，乐普生物在北京建设了GMP标准的2,000L抗体生产线并投产，目前还正在北京建设200L溶瘤病毒药物生产线。公司目前还在建上海的生物医药生产中心，包括初步设计产能12,000L的生产线及配套实验室和厂房的建设。依托公司的团队和技术平台，生产及商业化能力的建设也将为公司的全球化布局提供巨大支持。","news_type":1,"symbols_score_info":{"02157":0.9}},"isVote":1,"tweetType":1,"viewCount":1769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887756499,"gmtCreate":1632102009611,"gmtModify":1676530700701,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887756499","repostId":"1100031374","repostType":4,"repost":{"id":"1100031374","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631587259,"share":"https://ttm.financial/m/news/1100031374?lang=en_US&edition=fundamental","pubTime":"2021-09-14 10:40","market":"sg","language":"zh","title":"Reminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=1100031374","media":"老虎资讯综合","summary":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n\n\n9月22日（周三）休市。9月23日（周四）起照常开市。\n\n\nA股：\n\n\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n\n\n美股、英股、澳股、新加坡股市照常交易。\n\n\n沪股通和深股通：\n\n\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n\n\n港股通：\n\n\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","content":"<p>The 2021 Mid-Autumn Festival holiday is upon us! The closure arrangements for each of the major markets are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>Closed on Wednesday, September 22. The market will open as usual from September 23rd (Thursday).</p><p><b>A shares:</b></p><p>Closed from Monday, September 20th to Tuesday, September 21st. The market will open as usual from September 22nd (Wednesday).</p><p><b>US stocks, UK stocks, Australian stocks and Singapore stocks traded as usual.</b></p><p><b>Shanghai Stock Connect and Shenzhen Stock Connect:</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will be open as usual from Thursday, September 23rd.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed Thursday, Sept. 16 through Wednesday, Sept. 22. It will be open as usual from Thursday, September 23rd.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-14 10:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The 2021 Mid-Autumn Festival holiday is upon us! The closure arrangements for each of the major markets are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>Closed on Wednesday, September 22. The market will open as usual from September 23rd (Thursday).</p><p><b>A shares:</b></p><p>Closed from Monday, September 20th to Tuesday, September 21st. The market will open as usual from September 22nd (Wednesday).</p><p><b>US stocks, UK stocks, Australian stocks and Singapore stocks traded as usual.</b></p><p><b>Shanghai Stock Connect and Shenzhen Stock Connect:</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will be open as usual from Thursday, September 23rd.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed Thursday, Sept. 16 through Wednesday, Sept. 22. It will be open as usual from Thursday, September 23rd.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100031374","content_text":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n9月22日（周三）休市。9月23日（周四）起照常开市。\nA股：\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n美股、英股、澳股、新加坡股市照常交易。\n沪股通和深股通：\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n港股通：\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":743,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":833624200,"gmtCreate":1629241610600,"gmtModify":1676529973638,"author":{"id":"4089010487435940","authorId":"4089010487435940","name":"yapfuiping","avatar":"https://static.tigerbbs.com/3a27fbd615737b61aec5a628994a8a59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089010487435940","idStr":"4089010487435940"},"themes":[],"htmlText":"Buy now","listText":"Buy now","text":"Buy now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/833624200","repostId":"2160783852","repostType":2,"isVote":1,"tweetType":1,"viewCount":1147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}